TY  - JOUR
AU  - Đuriš, Jelena
AU  - Cvijić, Sandra
AU  - Đekić, Ljiljana
PY  - 2024
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5566
AB  - The pharmaceutical industry has faced significant changes in recent years, primarily influenced by regulatory standards, market competition, and the need to accelerate drug development. Model-informed drug development (MIDD) leverages quantitative computational models to facilitate decision-making processes. This approach sheds light on the complex interplay between the influence of a drug’s performance and the resulting clinical outcomes. This comprehensive review aims to explain the mechanisms that control the dissolution and/or release of drugs and their subsequent permeation through biological membranes. Furthermore, the importance of simulating these processes through a variety of in silico models is emphasized. Advanced compartmental absorption models provide an analytical framework to understand the kinetics of transit, dissolution, and absorption associated with orally administered drugs. In contrast, for topical and transdermal drug delivery systems, the prediction of drug permeation is predominantly based on quantitative structure–permeation relationships and molecular dynamics simulations. This review describes a variety of modeling strategies, ranging from mechanistic to empirical equations, and highlights the growing importance of state-of-the-art tools such as artificial intelligence, as well as advanced imaging and spectroscopic techniques.
PB  - MDPI
T2  - Pharmaceuticals
T1  - Model-Informed Drug Development: In Silico Assessment of Drug Bioperformance following Oral and Percutaneous Administration
VL  - 17
IS  - 2
DO  - 10.3390/ph17020177
ER  - 

@article{
author = "Đuriš, Jelena and Cvijić, Sandra and Đekić, Ljiljana",
year = "2024",
abstract = "The pharmaceutical industry has faced significant changes in recent years, primarily influenced by regulatory standards, market competition, and the need to accelerate drug development. Model-informed drug development (MIDD) leverages quantitative computational models to facilitate decision-making processes. This approach sheds light on the complex interplay between the influence of a drug’s performance and the resulting clinical outcomes. This comprehensive review aims to explain the mechanisms that control the dissolution and/or release of drugs and their subsequent permeation through biological membranes. Furthermore, the importance of simulating these processes through a variety of in silico models is emphasized. Advanced compartmental absorption models provide an analytical framework to understand the kinetics of transit, dissolution, and absorption associated with orally administered drugs. In contrast, for topical and transdermal drug delivery systems, the prediction of drug permeation is predominantly based on quantitative structure–permeation relationships and molecular dynamics simulations. This review describes a variety of modeling strategies, ranging from mechanistic to empirical equations, and highlights the growing importance of state-of-the-art tools such as artificial intelligence, as well as advanced imaging and spectroscopic techniques.",
publisher = "MDPI",
journal = "Pharmaceuticals",
title = "Model-Informed Drug Development: In Silico Assessment of Drug Bioperformance following Oral and Percutaneous Administration",
volume = "17",
number = "2",
doi = "10.3390/ph17020177"
}

Đuriš, J., Cvijić, S.,& Đekić, L.. (2024). Model-Informed Drug Development: In Silico Assessment of Drug Bioperformance following Oral and Percutaneous Administration. in Pharmaceuticals
MDPI., 17(2).
https://doi.org/10.3390/ph17020177

Đuriš J, Cvijić S, Đekić L. Model-Informed Drug Development: In Silico Assessment of Drug Bioperformance following Oral and Percutaneous Administration. in Pharmaceuticals. 2024;17(2).
doi:10.3390/ph17020177 .

Đuriš, Jelena, Cvijić, Sandra, Đekić, Ljiljana, "Model-Informed Drug Development: In Silico Assessment of Drug Bioperformance following Oral and Percutaneous Administration" in Pharmaceuticals, 17, no. 2 (2024),
https://doi.org/10.3390/ph17020177 . .

TY  - JOUR
AU  - Porat, Daniel
AU  - Dukhno, Oleg
AU  - Cvijić, Sandra
AU  - Dahan, Arik
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5393
AB  - Postbariatric altered gastrointestinal (GI) anatomy/physiology may significantly harm oral drug absorption and overall bioavailability. In this work, sildenafil, the first phosphodiesterase-5 (PDE5) inhibitor, was investigated for impaired postbariatric solubility/dissolution and absorption; this research question is of particular relevance since erectile dysfunction (ED) is associated with higher body mass index (BMI). Sildenafil solubility was determined both in vitro and ex vivo, using pre- vs. postsurgery gastric contents aspirated from patients. Dissolution tests were done in conditions mimicking the stomach before surgery, after sleeve gastrectomy (post-SG, pH 5), and after one anastomosis gastric bypass (post-OAGB, pH 7). Finally, these data were included in physiologically based pharmacokinetic (PBPK) modelling (GastroPlus®) to simulate sildenafil PK before vs. after surgery. pH-dependent solubility was demonstrated with low solubility (0.3 mg/mL) at pH 7 vs. high solubility at pH 1–5, which was also confirmed ex vivo with much lower solubility values in postbariatric gastric samples. Hampered dissolution of all sildenafil doses was obtained under post-OAGB conditions compared with complete (100%) dissolution under both presurgery and post-SG conditions. PBPK simulations revealed delayed sildenafil absorption in postbariatric patients (increased tmax) and reduced Cmax, especially in post-OAGB patients, relative to a presurgery state. Hence, the effect of bariatric surgery on sildenafil PK is unpredictable and may depend on the specific bariatric procedure. This mechanistically based analysis suggests a potentially undesirable delayed onset of action of sildenafil following gastric bypass surgery.
PB  - MDPI
T2  - Pharmaceutics
T1  - The Complexity of Bariatric Patient’s Pharmacotherapy: Sildenafil Biopharmaceutics and Pharmacokinetics before vs. after Gastric Sleeve/Bypass
VL  - 15
IS  - 12
DO  - 10.3390/pharmaceutics15122795
ER  - 

@article{
author = "Porat, Daniel and Dukhno, Oleg and Cvijić, Sandra and Dahan, Arik",
year = "2023",
abstract = "Postbariatric altered gastrointestinal (GI) anatomy/physiology may significantly harm oral drug absorption and overall bioavailability. In this work, sildenafil, the first phosphodiesterase-5 (PDE5) inhibitor, was investigated for impaired postbariatric solubility/dissolution and absorption; this research question is of particular relevance since erectile dysfunction (ED) is associated with higher body mass index (BMI). Sildenafil solubility was determined both in vitro and ex vivo, using pre- vs. postsurgery gastric contents aspirated from patients. Dissolution tests were done in conditions mimicking the stomach before surgery, after sleeve gastrectomy (post-SG, pH 5), and after one anastomosis gastric bypass (post-OAGB, pH 7). Finally, these data were included in physiologically based pharmacokinetic (PBPK) modelling (GastroPlus®) to simulate sildenafil PK before vs. after surgery. pH-dependent solubility was demonstrated with low solubility (0.3 mg/mL) at pH 7 vs. high solubility at pH 1–5, which was also confirmed ex vivo with much lower solubility values in postbariatric gastric samples. Hampered dissolution of all sildenafil doses was obtained under post-OAGB conditions compared with complete (100%) dissolution under both presurgery and post-SG conditions. PBPK simulations revealed delayed sildenafil absorption in postbariatric patients (increased tmax) and reduced Cmax, especially in post-OAGB patients, relative to a presurgery state. Hence, the effect of bariatric surgery on sildenafil PK is unpredictable and may depend on the specific bariatric procedure. This mechanistically based analysis suggests a potentially undesirable delayed onset of action of sildenafil following gastric bypass surgery.",
publisher = "MDPI",
journal = "Pharmaceutics",
title = "The Complexity of Bariatric Patient’s Pharmacotherapy: Sildenafil Biopharmaceutics and Pharmacokinetics before vs. after Gastric Sleeve/Bypass",
volume = "15",
number = "12",
doi = "10.3390/pharmaceutics15122795"
}

Porat, D., Dukhno, O., Cvijić, S.,& Dahan, A.. (2023). The Complexity of Bariatric Patient’s Pharmacotherapy: Sildenafil Biopharmaceutics and Pharmacokinetics before vs. after Gastric Sleeve/Bypass. in Pharmaceutics
MDPI., 15(12).
https://doi.org/10.3390/pharmaceutics15122795

Porat D, Dukhno O, Cvijić S, Dahan A. The Complexity of Bariatric Patient’s Pharmacotherapy: Sildenafil Biopharmaceutics and Pharmacokinetics before vs. after Gastric Sleeve/Bypass. in Pharmaceutics. 2023;15(12).
doi:10.3390/pharmaceutics15122795 .

Porat, Daniel, Dukhno, Oleg, Cvijić, Sandra, Dahan, Arik, "The Complexity of Bariatric Patient’s Pharmacotherapy: Sildenafil Biopharmaceutics and Pharmacokinetics before vs. after Gastric Sleeve/Bypass" in Pharmaceutics, 15, no. 12 (2023),
https://doi.org/10.3390/pharmaceutics15122795 . .

TY  - JOUR
AU  - Shi, Changzhi
AU  - Guo, Kewei
AU  - Zhang, Li
AU  - Guo, Yi
AU  - Feng, Yu
AU  - Cvijić, Sandra
AU  - Cun, Dongmei
AU  - Yang, Mingshi
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5080
AB  - Respiratory antibiotics delivery has been appreciated for its high local concentration at the infection sites. Certain formulation strategies are required to improve pulmonary drug exposure and to achieve effective antimicrobial activity, especially for highly permeable antibiotics. This study aimed to investigate lung exposure to various inhalable ciprofloxacin (CIP) formulations with different drug release rates in a rat model. Four formulations were prepared, i.e., CIP-loaded PLGA micro-particles (CHPM), CIP microcrystalline dry powder (CMDP), CIP nanocrystalline dry powder (CNDP), and CIP spray-dried powder (CHDP), which served as a reference. The physicochemical properties, drug dissolution rate, and aerosolization performance of these powders were characterized in vitro. Pharmacokinetic profiles were evaluated in rats. All formulations were suitable for inhalation (mass median aerodynamic diameter < 5 µm). CIP in CHPM and CHDP was amorphous, whereas the drug in CMDP and CNDP remained predominantly crystalline. CHDP exhibited the fastest drug release rate, while CMDP and CNDP exhibited much slower drug release. In addition, CMDP and CNDP exhibited significantly higher in vivo lung exposure to CIP compared with CHDP and CHPM. This study suggests that lung exposure to inhaled drugs with high permeability is governed by drug release rate, implying that lung exposure of inhaled antibiotics could be improved by a sustained-release formulation strategy.
PB  - MDPI
T2  - Pharmaceutics
T1  - In Vitro and In Vivo Evaluation of Inhalable Ciprofloxacin Sustained Release Formulations
VL  - 15
IS  - 9
DO  - 10.3390/pharmaceutics15092287
ER  - 

@article{
author = "Shi, Changzhi and Guo, Kewei and Zhang, Li and Guo, Yi and Feng, Yu and Cvijić, Sandra and Cun, Dongmei and Yang, Mingshi",
year = "2023",
abstract = "Respiratory antibiotics delivery has been appreciated for its high local concentration at the infection sites. Certain formulation strategies are required to improve pulmonary drug exposure and to achieve effective antimicrobial activity, especially for highly permeable antibiotics. This study aimed to investigate lung exposure to various inhalable ciprofloxacin (CIP) formulations with different drug release rates in a rat model. Four formulations were prepared, i.e., CIP-loaded PLGA micro-particles (CHPM), CIP microcrystalline dry powder (CMDP), CIP nanocrystalline dry powder (CNDP), and CIP spray-dried powder (CHDP), which served as a reference. The physicochemical properties, drug dissolution rate, and aerosolization performance of these powders were characterized in vitro. Pharmacokinetic profiles were evaluated in rats. All formulations were suitable for inhalation (mass median aerodynamic diameter < 5 µm). CIP in CHPM and CHDP was amorphous, whereas the drug in CMDP and CNDP remained predominantly crystalline. CHDP exhibited the fastest drug release rate, while CMDP and CNDP exhibited much slower drug release. In addition, CMDP and CNDP exhibited significantly higher in vivo lung exposure to CIP compared with CHDP and CHPM. This study suggests that lung exposure to inhaled drugs with high permeability is governed by drug release rate, implying that lung exposure of inhaled antibiotics could be improved by a sustained-release formulation strategy.",
publisher = "MDPI",
journal = "Pharmaceutics",
title = "In Vitro and In Vivo Evaluation of Inhalable Ciprofloxacin Sustained Release Formulations",
volume = "15",
number = "9",
doi = "10.3390/pharmaceutics15092287"
}

Shi, C., Guo, K., Zhang, L., Guo, Y., Feng, Y., Cvijić, S., Cun, D.,& Yang, M.. (2023). In Vitro and In Vivo Evaluation of Inhalable Ciprofloxacin Sustained Release Formulations. in Pharmaceutics
MDPI., 15(9).
https://doi.org/10.3390/pharmaceutics15092287

Shi C, Guo K, Zhang L, Guo Y, Feng Y, Cvijić S, Cun D, Yang M. In Vitro and In Vivo Evaluation of Inhalable Ciprofloxacin Sustained Release Formulations. in Pharmaceutics. 2023;15(9).
doi:10.3390/pharmaceutics15092287 .

Shi, Changzhi, Guo, Kewei, Zhang, Li, Guo, Yi, Feng, Yu, Cvijić, Sandra, Cun, Dongmei, Yang, Mingshi, "In Vitro and In Vivo Evaluation of Inhalable Ciprofloxacin Sustained Release Formulations" in Pharmaceutics, 15, no. 9 (2023),
https://doi.org/10.3390/pharmaceutics15092287 . .

TY  - CONF
AU  - Cvijić, Sandra
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5353
AB  - Poslednjih godina gojaznost postaje sve veći zdravstveni problem i za pacijente sa morbidnom
gojaznošću operacija želuca, odnosno, gastrični bajpas može da predstavlja najbolje rešenje (1).
Međutim, određene bolesti ili stanja koja prate gojaznost ostaju i nakon operacije, što za pacijente
podrazumeva kontinuiranu farmakoterapiju. U ovakvim slučajevima posebnu pažnju treba obratiti
na terapiju oralnim lekovima, jer kod barijatrijskih pacijenata često postoji potreba za podešavanjem
vrste, doze, režima doziranja i/ili farmaceutskog oblika leka (2,3). Naime, izmenjeni fiziološki uslovi
nakon operacije mogu značajno da utiču na brzinu rastvaranja i apsorpciju oralno primenjenih
lekova, u zavisnosti od osobina lekovite supstance i tipa hirurške procedure. Dodatno, trenutne
preporuke za oralnu primenu lekova barijatrijskim pacijentima, kao što su usitnjavanje tableta ili
otvaranje kapsula (kada je dozvoljeno), uglavnom ne mogu da prevaziđu probleme vezane za lošu
apsorpciju lekova, što dovodi do neuspeha terapije. Alternativni pristup u rešavanju ovakvih izazova
predstavlja fiziološki zasnovano biofarmaceutsko modelovanje (PBBM), kompjuterski podržana
metoda koja dovodi u vezu karakteristike lekovite supstance i farmaceutskog oblika leka sa
specifičnim fiziološkim uslovima, te omogućava predviđanje bioperformansi leka kod određenog
pacijenta ili u ciljanoj populaciji pacijenata. U ovom izlaganju će biti ilustrovani koncept i primena
PBBM modelovanja za specifičnu populaciju pacijenata, sa fokusom na primere koji opisuju odnos
između lek-specifičnih i fizioloških parametara koji utiču na ponašanje leka u organizmu. Izabrani
primeri pokazuju kako PBBM predviđanja, u kombinaciji sa in vitro određenim karakteristikama
lekovite supstance, mogu da se koriste za dobijanje odgovora na klinički značajna pitanja, poput
odabira odgovarajuće terapije za barijatrijske pacijente (4,5).
AB  - The prevalence of obesity has increased in recent years, and gastric bypass (bariatric) surgery
may be the best treatment option for patients with severe (morbid) obesity (1). Yet, bariatric patients
often suffer from concomitant diseases that require pharmacological treatment. In this context,
special attention should be paid to oral drug dosing, as bariatric patients may need adjusted
pharmacotherapy in terms of drug, dose/dosing regimen and/or dosage form selection (2,3). Namely,
altered physiological conditions after bariatric surgery can markedly affect dissolution and
absorption of orally administered drugs, depending on drug properties and the type of bariatric
procedure. In addition, currently suggested approaches for oral drug administration in bariatric
patients, such as crushing tablets or opening capsules (when permitted), generally fail to address the
issues related to poor drug absorption, resulting in therapeutic failures. An alternative to tackle these
challenges is physiologically based biopharmaceutical modeling (PBBM), a computer-based tool that
relates drug and dosage form properties to specific physiological conditions, thus allowing prediction
of drug bioperformance in a target patient or population group. This presentation will illustrate the
concept and implementation of PBBM modeling for special patient population, focusing on the
examples describing the interplay between drug-specific and physiologically relevant parameters
that determine drug performance in vivo. The selected examples will demonstrate how PBBM
predictions can be used in conjunction with in vitro data on drug properties to answer clinically
relevant questions, such as selecting appropriate drug therapy in bariatric patients (4,5).
PB  - Savez farmaceutskih udruženja Srbije
C3  - Arhiv za farmaciju
T1  - Izazovi u farmakoterapiji pacijenata nakon gastričnog bajpasa: predviđanje apsorpcije oralno primenjenih lekova
T1  - Tackling the challenges of pharmacotherapy in gastric bypass patients: prediction of oral drug absorption
VL  - 73
IS  - Suppl. 4
SP  - S15
EP  - S17
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5353
ER  - 

@conference{
author = "Cvijić, Sandra",
year = "2023",
abstract = "Poslednjih godina gojaznost postaje sve veći zdravstveni problem i za pacijente sa morbidnom
gojaznošću operacija želuca, odnosno, gastrični bajpas može da predstavlja najbolje rešenje (1).
Međutim, određene bolesti ili stanja koja prate gojaznost ostaju i nakon operacije, što za pacijente
podrazumeva kontinuiranu farmakoterapiju. U ovakvim slučajevima posebnu pažnju treba obratiti
na terapiju oralnim lekovima, jer kod barijatrijskih pacijenata često postoji potreba za podešavanjem
vrste, doze, režima doziranja i/ili farmaceutskog oblika leka (2,3). Naime, izmenjeni fiziološki uslovi
nakon operacije mogu značajno da utiču na brzinu rastvaranja i apsorpciju oralno primenjenih
lekova, u zavisnosti od osobina lekovite supstance i tipa hirurške procedure. Dodatno, trenutne
preporuke za oralnu primenu lekova barijatrijskim pacijentima, kao što su usitnjavanje tableta ili
otvaranje kapsula (kada je dozvoljeno), uglavnom ne mogu da prevaziđu probleme vezane za lošu
apsorpciju lekova, što dovodi do neuspeha terapije. Alternativni pristup u rešavanju ovakvih izazova
predstavlja fiziološki zasnovano biofarmaceutsko modelovanje (PBBM), kompjuterski podržana
metoda koja dovodi u vezu karakteristike lekovite supstance i farmaceutskog oblika leka sa
specifičnim fiziološkim uslovima, te omogućava predviđanje bioperformansi leka kod određenog
pacijenta ili u ciljanoj populaciji pacijenata. U ovom izlaganju će biti ilustrovani koncept i primena
PBBM modelovanja za specifičnu populaciju pacijenata, sa fokusom na primere koji opisuju odnos
između lek-specifičnih i fizioloških parametara koji utiču na ponašanje leka u organizmu. Izabrani
primeri pokazuju kako PBBM predviđanja, u kombinaciji sa in vitro određenim karakteristikama
lekovite supstance, mogu da se koriste za dobijanje odgovora na klinički značajna pitanja, poput
odabira odgovarajuće terapije za barijatrijske pacijente (4,5)., The prevalence of obesity has increased in recent years, and gastric bypass (bariatric) surgery
may be the best treatment option for patients with severe (morbid) obesity (1). Yet, bariatric patients
often suffer from concomitant diseases that require pharmacological treatment. In this context,
special attention should be paid to oral drug dosing, as bariatric patients may need adjusted
pharmacotherapy in terms of drug, dose/dosing regimen and/or dosage form selection (2,3). Namely,
altered physiological conditions after bariatric surgery can markedly affect dissolution and
absorption of orally administered drugs, depending on drug properties and the type of bariatric
procedure. In addition, currently suggested approaches for oral drug administration in bariatric
patients, such as crushing tablets or opening capsules (when permitted), generally fail to address the
issues related to poor drug absorption, resulting in therapeutic failures. An alternative to tackle these
challenges is physiologically based biopharmaceutical modeling (PBBM), a computer-based tool that
relates drug and dosage form properties to specific physiological conditions, thus allowing prediction
of drug bioperformance in a target patient or population group. This presentation will illustrate the
concept and implementation of PBBM modeling for special patient population, focusing on the
examples describing the interplay between drug-specific and physiologically relevant parameters
that determine drug performance in vivo. The selected examples will demonstrate how PBBM
predictions can be used in conjunction with in vitro data on drug properties to answer clinically
relevant questions, such as selecting appropriate drug therapy in bariatric patients (4,5).",
publisher = "Savez farmaceutskih udruženja Srbije",
journal = "Arhiv za farmaciju",
title = "Izazovi u farmakoterapiji pacijenata nakon gastričnog bajpasa: predviđanje apsorpcije oralno primenjenih lekova, Tackling the challenges of pharmacotherapy in gastric bypass patients: prediction of oral drug absorption",
volume = "73",
number = "Suppl. 4",
pages = "S15-S17",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5353"
}

Cvijić, S.. (2023). Izazovi u farmakoterapiji pacijenata nakon gastričnog bajpasa: predviđanje apsorpcije oralno primenjenih lekova. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije., 73(Suppl. 4), S15-S17.
https://hdl.handle.net/21.15107/rcub_farfar_5353

Cvijić S. Izazovi u farmakoterapiji pacijenata nakon gastričnog bajpasa: predviđanje apsorpcije oralno primenjenih lekova. in Arhiv za farmaciju. 2023;73(Suppl. 4):S15-S17.
https://hdl.handle.net/21.15107/rcub_farfar_5353 .

Cvijić, Sandra, "Izazovi u farmakoterapiji pacijenata nakon gastričnog bajpasa: predviđanje apsorpcije oralno primenjenih lekova" in Arhiv za farmaciju, 73, no. Suppl. 4 (2023):S15-S17,
https://hdl.handle.net/21.15107/rcub_farfar_5353 .

TY  - CONF
AU  - Đuranović, Marija
AU  - Grujić, Branka
AU  - Cvijić, Sandra
AU  - Ibrić, Svetlana
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5336
AB  - Deponovanje istopljenog filamenta (FDM) je jedna od najviše istraživanih tehnika 3D štampe,
čiji princip rada se zasniva na depoziciji tankih polimernih niti na ravnu ploču, sloj po sloj. Postoji veliki broj parametara štampe koji se mogu podešavati u FDM 3D tehnici, a neki od njih su: temperatura štampe, brzina štampe, obrazac punjenja, gustina punjenja itd. Navedeni parametric mogu imati uticaj na brzinu oslobadđanja ljekovite supstance iz 3D odštampanih farmaceutskih preparata. Cilj ovog rada bio je da se ispita uticaj obrasca punjenja na brzinu oslobađanja paracetamola iz FDM 3D tabteta zasnovanih na polivinil alkoholu (PVA). ...
AB  - Fused deposition modelling (FDM) is currently one of the most commonly used technique in
3D printing and its principle is based on deposition of thin polymer strands on a build plate, in a
layer-by-layer manner. The whole process is controlled by a software. There are many printing
parameters in FDM 3D printing technique that can be varied, such as: printing temperature,
printing speed, infill density, infill pattern etc. ...
PB  - Farmaceutska komora Crne Gore
PB  - Univerzitet Crne Gore, Medicinski fakultet, studijski program-farmacija
C3  - 4. kongres farmaceuta Crne Gore sa međunarodnim učešćem, 11-14. maj 2023. Budva, Bečići, Crna Gora, Zbornik sažetaka
T1  - Ispitivanje uticaja obrasca punjenja na brzinu oslobađanja lekovite supstance iz šupljih tableta paracetamola izrađenih tehnikom 3D štampe deponovanjem istopljenog filamenta
T1  - The evaluation of the effect of different infill patterns on the drug release from hollow paracetamol-loaded tablets 3D printed via fused deposition modelling technique
VL  - PP-18
SP  - 116
EP  - 117
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5336
ER  - 

@conference{
author = "Đuranović, Marija and Grujić, Branka and Cvijić, Sandra and Ibrić, Svetlana",
year = "2023",
abstract = "Deponovanje istopljenog filamenta (FDM) je jedna od najviše istraživanih tehnika 3D štampe,
čiji princip rada se zasniva na depoziciji tankih polimernih niti na ravnu ploču, sloj po sloj. Postoji veliki broj parametara štampe koji se mogu podešavati u FDM 3D tehnici, a neki od njih su: temperatura štampe, brzina štampe, obrazac punjenja, gustina punjenja itd. Navedeni parametric mogu imati uticaj na brzinu oslobadđanja ljekovite supstance iz 3D odštampanih farmaceutskih preparata. Cilj ovog rada bio je da se ispita uticaj obrasca punjenja na brzinu oslobađanja paracetamola iz FDM 3D tabteta zasnovanih na polivinil alkoholu (PVA). ..., Fused deposition modelling (FDM) is currently one of the most commonly used technique in
3D printing and its principle is based on deposition of thin polymer strands on a build plate, in a
layer-by-layer manner. The whole process is controlled by a software. There are many printing
parameters in FDM 3D printing technique that can be varied, such as: printing temperature,
printing speed, infill density, infill pattern etc. ...",
publisher = "Farmaceutska komora Crne Gore, Univerzitet Crne Gore, Medicinski fakultet, studijski program-farmacija",
journal = "4. kongres farmaceuta Crne Gore sa međunarodnim učešćem, 11-14. maj 2023. Budva, Bečići, Crna Gora, Zbornik sažetaka",
title = "Ispitivanje uticaja obrasca punjenja na brzinu oslobađanja lekovite supstance iz šupljih tableta paracetamola izrađenih tehnikom 3D štampe deponovanjem istopljenog filamenta, The evaluation of the effect of different infill patterns on the drug release from hollow paracetamol-loaded tablets 3D printed via fused deposition modelling technique",
volume = "PP-18",
pages = "116-117",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5336"
}

Đuranović, M., Grujić, B., Cvijić, S.,& Ibrić, S.. (2023). Ispitivanje uticaja obrasca punjenja na brzinu oslobađanja lekovite supstance iz šupljih tableta paracetamola izrađenih tehnikom 3D štampe deponovanjem istopljenog filamenta. in 4. kongres farmaceuta Crne Gore sa međunarodnim učešćem, 11-14. maj 2023. Budva, Bečići, Crna Gora, Zbornik sažetaka
Farmaceutska komora Crne Gore., PP-18, 116-117.
https://hdl.handle.net/21.15107/rcub_farfar_5336

Đuranović M, Grujić B, Cvijić S, Ibrić S. Ispitivanje uticaja obrasca punjenja na brzinu oslobađanja lekovite supstance iz šupljih tableta paracetamola izrađenih tehnikom 3D štampe deponovanjem istopljenog filamenta. in 4. kongres farmaceuta Crne Gore sa međunarodnim učešćem, 11-14. maj 2023. Budva, Bečići, Crna Gora, Zbornik sažetaka. 2023;PP-18:116-117.
https://hdl.handle.net/21.15107/rcub_farfar_5336 .

Đuranović, Marija, Grujić, Branka, Cvijić, Sandra, Ibrić, Svetlana, "Ispitivanje uticaja obrasca punjenja na brzinu oslobađanja lekovite supstance iz šupljih tableta paracetamola izrađenih tehnikom 3D štampe deponovanjem istopljenog filamenta" in 4. kongres farmaceuta Crne Gore sa međunarodnim učešćem, 11-14. maj 2023. Budva, Bečići, Crna Gora, Zbornik sažetaka, PP-18 (2023):116-117,
https://hdl.handle.net/21.15107/rcub_farfar_5336 .

TY  - JOUR
AU  - Porat, Daniel
AU  - Dukhno, Oleg
AU  - Partook-Maccabi, Mazal
AU  - Vainer, Ella
AU  - Cvijić, Sandra
AU  - Dahan, Arik
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5038
AB  - Anatomical/physiological gastrointestinal changes after bariatric surgery may influence the fate of orally administered drugs. Since non-selective NSAIDs are not well-tolerated post-surgery, selective cyclooxygenase-2 (COX-2) inhibitors may be important for these patients. In this work we investigated celecoxib, etoricoxib and etodolac, for impaired post-bariatric solubility/dissolution and absorption. Solubility was studied in-vitro, and ex-vivo in aspirated gastric contents from patients pre- vs. post-surgery. Dissolution was studied in conditions simulating pre- vs. post-surgery stomach. Finally, the experimental solubility data were used in physiologically-based biopharmaceutics model (PBBM) (GastroPlus®) to simulate pre- vs. post-surgery celecoxib/etoricoxib/etodolac pharmacokinetic (PK) profiles. For etoricoxib and etodolac (but not celecoxib), pH-dependent solubility was demonstrated: etoricoxib solubility decreased ∼1000-fold, and etodolac solubility increased 120-fold, as pH increased from 1 to 7, which was also confirmed ex-vivo. Hampered etoricoxib dissolution and improved etodolac dissolution post-surgery was revealed. Tablet crushing, clinically recommended after surgery, failed to improve post-bariatric dissolution. PBBM simulations revealed significantly impaired etoricoxib absorption post-surgery across all conditions; for instance, 79% lower Cmax and 53% decreased AUC was simulated post-gastric bypass procedure, after single 120 mg dose. Celecoxib and etodolac maintained unaffected absorption after bariatric surgery. This mechanistically-based analysis suggests to prefer the acidic drug etodolac or the neutral celecoxib as selective COX-2 inhibitors, over the basic drug etoricoxib, after bariatric surgery.
PB  - Elsevier B.V.
T2  - International Journal of Pharmaceutics
T1  - Selective COX-2 inhibitors after bariatric surgery: Celecoxib, etoricoxib and etodolac post-bariatric solubility/dissolution and pharmacokinetics
VL  - 645
DO  - 10.1016/j.ijpharm.2023.123347
ER  - 

@article{
author = "Porat, Daniel and Dukhno, Oleg and Partook-Maccabi, Mazal and Vainer, Ella and Cvijić, Sandra and Dahan, Arik",
year = "2023",
abstract = "Anatomical/physiological gastrointestinal changes after bariatric surgery may influence the fate of orally administered drugs. Since non-selective NSAIDs are not well-tolerated post-surgery, selective cyclooxygenase-2 (COX-2) inhibitors may be important for these patients. In this work we investigated celecoxib, etoricoxib and etodolac, for impaired post-bariatric solubility/dissolution and absorption. Solubility was studied in-vitro, and ex-vivo in aspirated gastric contents from patients pre- vs. post-surgery. Dissolution was studied in conditions simulating pre- vs. post-surgery stomach. Finally, the experimental solubility data were used in physiologically-based biopharmaceutics model (PBBM) (GastroPlus®) to simulate pre- vs. post-surgery celecoxib/etoricoxib/etodolac pharmacokinetic (PK) profiles. For etoricoxib and etodolac (but not celecoxib), pH-dependent solubility was demonstrated: etoricoxib solubility decreased ∼1000-fold, and etodolac solubility increased 120-fold, as pH increased from 1 to 7, which was also confirmed ex-vivo. Hampered etoricoxib dissolution and improved etodolac dissolution post-surgery was revealed. Tablet crushing, clinically recommended after surgery, failed to improve post-bariatric dissolution. PBBM simulations revealed significantly impaired etoricoxib absorption post-surgery across all conditions; for instance, 79% lower Cmax and 53% decreased AUC was simulated post-gastric bypass procedure, after single 120 mg dose. Celecoxib and etodolac maintained unaffected absorption after bariatric surgery. This mechanistically-based analysis suggests to prefer the acidic drug etodolac or the neutral celecoxib as selective COX-2 inhibitors, over the basic drug etoricoxib, after bariatric surgery.",
publisher = "Elsevier B.V.",
journal = "International Journal of Pharmaceutics",
title = "Selective COX-2 inhibitors after bariatric surgery: Celecoxib, etoricoxib and etodolac post-bariatric solubility/dissolution and pharmacokinetics",
volume = "645",
doi = "10.1016/j.ijpharm.2023.123347"
}

Porat, D., Dukhno, O., Partook-Maccabi, M., Vainer, E., Cvijić, S.,& Dahan, A.. (2023). Selective COX-2 inhibitors after bariatric surgery: Celecoxib, etoricoxib and etodolac post-bariatric solubility/dissolution and pharmacokinetics. in International Journal of Pharmaceutics
Elsevier B.V.., 645.
https://doi.org/10.1016/j.ijpharm.2023.123347

Porat D, Dukhno O, Partook-Maccabi M, Vainer E, Cvijić S, Dahan A. Selective COX-2 inhibitors after bariatric surgery: Celecoxib, etoricoxib and etodolac post-bariatric solubility/dissolution and pharmacokinetics. in International Journal of Pharmaceutics. 2023;645.
doi:10.1016/j.ijpharm.2023.123347 .

Porat, Daniel, Dukhno, Oleg, Partook-Maccabi, Mazal, Vainer, Ella, Cvijić, Sandra, Dahan, Arik, "Selective COX-2 inhibitors after bariatric surgery: Celecoxib, etoricoxib and etodolac post-bariatric solubility/dissolution and pharmacokinetics" in International Journal of Pharmaceutics, 645 (2023),
https://doi.org/10.1016/j.ijpharm.2023.123347 . .

TY  - JOUR
AU  - Kurćubić, Ivana
AU  - Đuriš, Jelena
AU  - Cvijić, Sandra
AU  - Crevar, Milkica
AU  - Ibrić, Svetlana
AU  - Miloradović, Zoran
AU  - Mihailović-Stanojević, Nevena
AU  - Karanović, Danijela
AU  - Ivanov, Milan
AU  - Jovović, Đurđica
AU  - Vajić, Una-Jovana
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4932
AB  - In order to exploit the advantage of drug delivery through the buccal mucosa, mucoadhesive buccal films with propranolol hydrochloride based on polyethylene oxide, hydroxypropyl methylcellulose, and polyvinyl alcohol have been developed. The aim of this study was the development, pharmaceutical-technological (uniformity of mass and drug content, film thickness, potential interactions between polymers and propranolol hydrochloride, in vitro drug permeation and drug release, mechanical and mucoadhesive properties), and biopharmaceutical characterization of prepared mucoadhesive buccal films through conducting in vivo study in spontaneously hypertensive rats and in silico modeling of intraoral and gastrointestinal drug absorption. For in vivo study formulation F2 (hydroxypropylmethyl cellulose 0.5%, polyethylene oxide 3.5%, polyvinyl alcohol 1.5%, propylene glycol 3%, and propranolol hydrochloride 2%) was selected, which showed the highest values of tensile strength and percentage of elongation, as well as the highest value of the force of adhesion. Results of pharmacokinetic in rats and in silico modeling confirmed the superiority of the mucoadhesive buccal films over immediate-release tablets (in rats: AUC0→24h 66.13 ± 18.03 vs. 24.61 ± 5.52 μg⋅h/mL, AUC0→∞ 111.82 ± 39.04 vs. 47.85 ± 11.67 μg⋅h/mL; in silico: AUC0→24h 200.17 vs.74.58 ng⋅h/mL, AUC0→∞ 204.04 vs. 75.64 ng⋅h/mL). Hemodynamic measurements have shown that mucoadhesive buccal films, compared to immediate-release tablets, provide a more pronounced decrease primarily in heart rate (28-51%), but also in diastolic pressure (up to 33%), as well as a longer heart rate reduction that was maintained for up to 12th h. Therefore, mucoadhesive buccal films increased the degree of absorbed drug and thus contributed to better therapeutic outcomes compared to immediate-release tablets for peroral administration.
PB  - Elsevier
T2  - Journal of Drug Delivery Science and Technology
T1  - Integrated in vitro – in vivo – in silico studies in the pharmaceutical development of propranolol hydrochloride mucoadhesive buccal films
VL  - 86
DO  - 10.1016/j.jddst.2023.104715
ER  - 

@article{
author = "Kurćubić, Ivana and Đuriš, Jelena and Cvijić, Sandra and Crevar, Milkica and Ibrić, Svetlana and Miloradović, Zoran and Mihailović-Stanojević, Nevena and Karanović, Danijela and Ivanov, Milan and Jovović, Đurđica and Vajić, Una-Jovana",
year = "2023",
abstract = "In order to exploit the advantage of drug delivery through the buccal mucosa, mucoadhesive buccal films with propranolol hydrochloride based on polyethylene oxide, hydroxypropyl methylcellulose, and polyvinyl alcohol have been developed. The aim of this study was the development, pharmaceutical-technological (uniformity of mass and drug content, film thickness, potential interactions between polymers and propranolol hydrochloride, in vitro drug permeation and drug release, mechanical and mucoadhesive properties), and biopharmaceutical characterization of prepared mucoadhesive buccal films through conducting in vivo study in spontaneously hypertensive rats and in silico modeling of intraoral and gastrointestinal drug absorption. For in vivo study formulation F2 (hydroxypropylmethyl cellulose 0.5%, polyethylene oxide 3.5%, polyvinyl alcohol 1.5%, propylene glycol 3%, and propranolol hydrochloride 2%) was selected, which showed the highest values of tensile strength and percentage of elongation, as well as the highest value of the force of adhesion. Results of pharmacokinetic in rats and in silico modeling confirmed the superiority of the mucoadhesive buccal films over immediate-release tablets (in rats: AUC0→24h 66.13 ± 18.03 vs. 24.61 ± 5.52 μg⋅h/mL, AUC0→∞ 111.82 ± 39.04 vs. 47.85 ± 11.67 μg⋅h/mL; in silico: AUC0→24h 200.17 vs.74.58 ng⋅h/mL, AUC0→∞ 204.04 vs. 75.64 ng⋅h/mL). Hemodynamic measurements have shown that mucoadhesive buccal films, compared to immediate-release tablets, provide a more pronounced decrease primarily in heart rate (28-51%), but also in diastolic pressure (up to 33%), as well as a longer heart rate reduction that was maintained for up to 12th h. Therefore, mucoadhesive buccal films increased the degree of absorbed drug and thus contributed to better therapeutic outcomes compared to immediate-release tablets for peroral administration.",
publisher = "Elsevier",
journal = "Journal of Drug Delivery Science and Technology",
title = "Integrated in vitro – in vivo – in silico studies in the pharmaceutical development of propranolol hydrochloride mucoadhesive buccal films",
volume = "86",
doi = "10.1016/j.jddst.2023.104715"
}

Kurćubić, I., Đuriš, J., Cvijić, S., Crevar, M., Ibrić, S., Miloradović, Z., Mihailović-Stanojević, N., Karanović, D., Ivanov, M., Jovović, Đ.,& Vajić, U.. (2023). Integrated in vitro – in vivo – in silico studies in the pharmaceutical development of propranolol hydrochloride mucoadhesive buccal films. in Journal of Drug Delivery Science and Technology
Elsevier., 86.
https://doi.org/10.1016/j.jddst.2023.104715

Kurćubić I, Đuriš J, Cvijić S, Crevar M, Ibrić S, Miloradović Z, Mihailović-Stanojević N, Karanović D, Ivanov M, Jovović Đ, Vajić U. Integrated in vitro – in vivo – in silico studies in the pharmaceutical development of propranolol hydrochloride mucoadhesive buccal films. in Journal of Drug Delivery Science and Technology. 2023;86.
doi:10.1016/j.jddst.2023.104715 .

Kurćubić, Ivana, Đuriš, Jelena, Cvijić, Sandra, Crevar, Milkica, Ibrić, Svetlana, Miloradović, Zoran, Mihailović-Stanojević, Nevena, Karanović, Danijela, Ivanov, Milan, Jovović, Đurđica, Vajić, Una-Jovana, "Integrated in vitro – in vivo – in silico studies in the pharmaceutical development of propranolol hydrochloride mucoadhesive buccal films" in Journal of Drug Delivery Science and Technology, 86 (2023),
https://doi.org/10.1016/j.jddst.2023.104715 . .

TY  - JOUR
AU  - Krstevska, Aleksandra
AU  - Đuriš, Jelena
AU  - Ibrić, Svetlana
AU  - Cvijić, Sandra
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4420
AB  - In the past decade, only a small number of papers have elaborated on the application of physiologically based pharmacokinetic (PBPK) modeling across different areas. In this review, an in-depth analysis of the distribution of PBPK modeling in relation to its application in various research topics and model validation was conducted by text mining tools. Orange 3.32.0, an open-source data mining program was used for text mining. PubMed was used for data retrieval, and the collected articles were analyzed by several widgets. A total of 2699 articles related to PBPK modeling met the predefined criteria. The number of publications per year has been rising steadily. Regarding the application areas, the results revealed that 26% of the publications described the use of PBPK modeling in early drug development, risk assessment and toxicity assessment, followed by absorption/formulation modeling (25%), prediction of drug-disease interactions (20%), drug-drug interactions (DDIs) (17%) and pediatric drug development (12%). Furthermore, the analysis showed that only 12% of the publications mentioned model validation, of which 51% referred to literature-based validation and 26% to experimentally validated models. The obtained results present a valuable review of the state-of-the-art regarding PBPK modeling applications in drug discovery and development and related fields.
PB  - MDPI
T2  - Pharmaceutics
T1  - In-Depth Analysis of Physiologically Based Pharmacokinetic (PBPK) Modeling Utilization in Different Application Fields Using Text Mining Tools
VL  - 15
IS  - 1
DO  - 10.3390/pharmaceutics15010107
ER  - 

@article{
author = "Krstevska, Aleksandra and Đuriš, Jelena and Ibrić, Svetlana and Cvijić, Sandra",
year = "2023",
abstract = "In the past decade, only a small number of papers have elaborated on the application of physiologically based pharmacokinetic (PBPK) modeling across different areas. In this review, an in-depth analysis of the distribution of PBPK modeling in relation to its application in various research topics and model validation was conducted by text mining tools. Orange 3.32.0, an open-source data mining program was used for text mining. PubMed was used for data retrieval, and the collected articles were analyzed by several widgets. A total of 2699 articles related to PBPK modeling met the predefined criteria. The number of publications per year has been rising steadily. Regarding the application areas, the results revealed that 26% of the publications described the use of PBPK modeling in early drug development, risk assessment and toxicity assessment, followed by absorption/formulation modeling (25%), prediction of drug-disease interactions (20%), drug-drug interactions (DDIs) (17%) and pediatric drug development (12%). Furthermore, the analysis showed that only 12% of the publications mentioned model validation, of which 51% referred to literature-based validation and 26% to experimentally validated models. The obtained results present a valuable review of the state-of-the-art regarding PBPK modeling applications in drug discovery and development and related fields.",
publisher = "MDPI",
journal = "Pharmaceutics",
title = "In-Depth Analysis of Physiologically Based Pharmacokinetic (PBPK) Modeling Utilization in Different Application Fields Using Text Mining Tools",
volume = "15",
number = "1",
doi = "10.3390/pharmaceutics15010107"
}

Krstevska, A., Đuriš, J., Ibrić, S.,& Cvijić, S.. (2023). In-Depth Analysis of Physiologically Based Pharmacokinetic (PBPK) Modeling Utilization in Different Application Fields Using Text Mining Tools. in Pharmaceutics
MDPI., 15(1).
https://doi.org/10.3390/pharmaceutics15010107

Krstevska A, Đuriš J, Ibrić S, Cvijić S. In-Depth Analysis of Physiologically Based Pharmacokinetic (PBPK) Modeling Utilization in Different Application Fields Using Text Mining Tools. in Pharmaceutics. 2023;15(1).
doi:10.3390/pharmaceutics15010107 .

Krstevska, Aleksandra, Đuriš, Jelena, Ibrić, Svetlana, Cvijić, Sandra, "In-Depth Analysis of Physiologically Based Pharmacokinetic (PBPK) Modeling Utilization in Different Application Fields Using Text Mining Tools" in Pharmaceutics, 15, no. 1 (2023),
https://doi.org/10.3390/pharmaceutics15010107 . .

TY  - CONF
AU  - Krstevska, Aleksandra
AU  - Đuriš, Jelena
AU  - Ibrić, Svetlana
AU  - Cvijić, Sandra
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5068
AB  - Physiologically based pharmacokinetic (PBPK)
modeling is an evolving tool that has a profound impact on
drug discovery and formulation development processes. A
major advantage of PBPK models is that they have the
ability to mechanistically explain how drug properties,
product quality attributes and physiological factors
influence the in vivo drug performance. To better specify
the application field of these models and highlight the link
between in vitro dissolution and drug’s in vivo behavior, a
novel term, physiologically based biopharmaceutics
modeling (PBBM), was recently introduced.
The versatility of application of these models is
perceived through the growth in the number of scientific
publications that include the use of PBPK/PBBM
(Krstevska et al, 2022). In the present study, the use of
PBPK/PBBM across the publications from the past decade
was analyzed, with the focus on the application of these
models in pharmaceutical/formulation development.
PB  - Macedonian Pharmaceutical Association
PB  - Ss. Cyril and Methodius University in Skopje, Faculty of Pharmacy
C3  - Macedonian Pharmaceutical Bulletin
T1  - A text mining study on the utility of physiologically based pharmacokinetic/biopharmaceutics modeling (PBPK/PBBM) in formulation development
VL  - 69
IS  - Suppl 1
SP  - 145
EP  - 146
DO  - 10.33320/maced.pharm.bull.2023.69.03.071
ER  - 

@conference{
author = "Krstevska, Aleksandra and Đuriš, Jelena and Ibrić, Svetlana and Cvijić, Sandra",
year = "2023",
abstract = "Physiologically based pharmacokinetic (PBPK)
modeling is an evolving tool that has a profound impact on
drug discovery and formulation development processes. A
major advantage of PBPK models is that they have the
ability to mechanistically explain how drug properties,
product quality attributes and physiological factors
influence the in vivo drug performance. To better specify
the application field of these models and highlight the link
between in vitro dissolution and drug’s in vivo behavior, a
novel term, physiologically based biopharmaceutics
modeling (PBBM), was recently introduced.
The versatility of application of these models is
perceived through the growth in the number of scientific
publications that include the use of PBPK/PBBM
(Krstevska et al, 2022). In the present study, the use of
PBPK/PBBM across the publications from the past decade
was analyzed, with the focus on the application of these
models in pharmaceutical/formulation development.",
publisher = "Macedonian Pharmaceutical Association, Ss. Cyril and Methodius University in Skopje, Faculty of Pharmacy",
journal = "Macedonian Pharmaceutical Bulletin",
title = "A text mining study on the utility of physiologically based pharmacokinetic/biopharmaceutics modeling (PBPK/PBBM) in formulation development",
volume = "69",
number = "Suppl 1",
pages = "145-146",
doi = "10.33320/maced.pharm.bull.2023.69.03.071"
}

Krstevska, A., Đuriš, J., Ibrić, S.,& Cvijić, S.. (2023). A text mining study on the utility of physiologically based pharmacokinetic/biopharmaceutics modeling (PBPK/PBBM) in formulation development. in Macedonian Pharmaceutical Bulletin
Macedonian Pharmaceutical Association., 69(Suppl 1), 145-146.
https://doi.org/10.33320/maced.pharm.bull.2023.69.03.071

Krstevska A, Đuriš J, Ibrić S, Cvijić S. A text mining study on the utility of physiologically based pharmacokinetic/biopharmaceutics modeling (PBPK/PBBM) in formulation development. in Macedonian Pharmaceutical Bulletin. 2023;69(Suppl 1):145-146.
doi:10.33320/maced.pharm.bull.2023.69.03.071 .

Krstevska, Aleksandra, Đuriš, Jelena, Ibrić, Svetlana, Cvijić, Sandra, "A text mining study on the utility of physiologically based pharmacokinetic/biopharmaceutics modeling (PBPK/PBBM) in formulation development" in Macedonian Pharmaceutical Bulletin, 69, no. Suppl 1 (2023):145-146,
https://doi.org/10.33320/maced.pharm.bull.2023.69.03.071 . .

TY  - CONF
AU  - Krstevska, Aleksandra
AU  - Nedelkov, Ivana
AU  - Petrović, Maša
AU  - Ibrić, Svetlana
AU  - Mirković, Dušica
AU  - Cvijić, Sandra
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5053
AB  - Precipitation of a drug substance in the small intestine
is a phenomenon relevant to weak bases due to their pH-
dependent solubility. Because of the low solubility at
higher pH, upon entry in the small intestine, a weak base
may get into a supersaturated state, which is
thermodynamically unstable and tends to precipitate
(Makitalo, 2019). Consequently, precipitation in the
gastrointestinal (GI) tract may significantly limit oral
bioavailability (BA) of poorly soluble, weak bases.
Several in vitro and in silico tools are available for
assessing the precipitation kinetics of weakly basic
compounds (Kou et al., 2018). The dynamic nature of
physiologically based in silico models and their ability to
treat drug dissolution and precipitation as variables
affecting concomitant drug bioperformance make in silico
models a powerful tool to assess the impact of these
variables on drug absorption.
The aim of this work was to in silico evaluate the
influence of possible variations in the values of GI
physiological parameters on the potential precipitation and
absorption of a weakly basic, poorly soluble and highly
permeable compound. ...
PB  - Macedonian Pharmaceutical Association
PB  - Ss. Cyril and Methodius University in Skopje, Faculty of Pharmacy
C3  - Macedonian Pharmaceutical Bulletin
T1  - In silico assessment of intestinal precipitation: Case study of a poorly soluble, weakly basic compound
VL  - 69
IS  - Suppl 1
SP  - 127
EP  - 128
DO  - 10.33320/maced.pharm.bull.2023.69.03.062
ER  - 

@conference{
author = "Krstevska, Aleksandra and Nedelkov, Ivana and Petrović, Maša and Ibrić, Svetlana and Mirković, Dušica and Cvijić, Sandra",
year = "2023",
abstract = "Precipitation of a drug substance in the small intestine
is a phenomenon relevant to weak bases due to their pH-
dependent solubility. Because of the low solubility at
higher pH, upon entry in the small intestine, a weak base
may get into a supersaturated state, which is
thermodynamically unstable and tends to precipitate
(Makitalo, 2019). Consequently, precipitation in the
gastrointestinal (GI) tract may significantly limit oral
bioavailability (BA) of poorly soluble, weak bases.
Several in vitro and in silico tools are available for
assessing the precipitation kinetics of weakly basic
compounds (Kou et al., 2018). The dynamic nature of
physiologically based in silico models and their ability to
treat drug dissolution and precipitation as variables
affecting concomitant drug bioperformance make in silico
models a powerful tool to assess the impact of these
variables on drug absorption.
The aim of this work was to in silico evaluate the
influence of possible variations in the values of GI
physiological parameters on the potential precipitation and
absorption of a weakly basic, poorly soluble and highly
permeable compound. ...",
publisher = "Macedonian Pharmaceutical Association, Ss. Cyril and Methodius University in Skopje, Faculty of Pharmacy",
journal = "Macedonian Pharmaceutical Bulletin",
title = "In silico assessment of intestinal precipitation: Case study of a poorly soluble, weakly basic compound",
volume = "69",
number = "Suppl 1",
pages = "127-128",
doi = "10.33320/maced.pharm.bull.2023.69.03.062"
}

Krstevska, A., Nedelkov, I., Petrović, M., Ibrić, S., Mirković, D.,& Cvijić, S.. (2023). In silico assessment of intestinal precipitation: Case study of a poorly soluble, weakly basic compound. in Macedonian Pharmaceutical Bulletin
Macedonian Pharmaceutical Association., 69(Suppl 1), 127-128.
https://doi.org/10.33320/maced.pharm.bull.2023.69.03.062

Krstevska A, Nedelkov I, Petrović M, Ibrić S, Mirković D, Cvijić S. In silico assessment of intestinal precipitation: Case study of a poorly soluble, weakly basic compound. in Macedonian Pharmaceutical Bulletin. 2023;69(Suppl 1):127-128.
doi:10.33320/maced.pharm.bull.2023.69.03.062 .

Krstevska, Aleksandra, Nedelkov, Ivana, Petrović, Maša, Ibrić, Svetlana, Mirković, Dušica, Cvijić, Sandra, "In silico assessment of intestinal precipitation: Case study of a poorly soluble, weakly basic compound" in Macedonian Pharmaceutical Bulletin, 69, no. Suppl 1 (2023):127-128,
https://doi.org/10.33320/maced.pharm.bull.2023.69.03.062 . .

TY  - CONF
AU  - Cvijić, Sandra
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5008
AB  - Physiologically based pharmacokinetic (PBPK) modeling or more recently also known as physiologically based biopharmaceutics modeling (PBBM) is a computer-aided (in silico) biopharmaceutical tool, designed to mechanistically describe bioperformance of a drug and predict its absorption and systemic availability. PBPK/PBBM was quickly adopted by pharmaceutical companies and medical regulatory agencies, its scope has expanded over the years, and nowadays PBPK/PBBM represents an essential tool in various phases of drug and formulation development (1). 
A major advantage of PBPK modeling over traditional in vitro and preclinical animal studies is the ability to link the physicochemical properties of a drug to its dissolution, absorption and disposition in a target patient or population, taking into account specific physiological conditions. This is accomplished through linked differential equations that describe simulta-neous or sequential dynamic processes that a drug undergoes in the body following dif-ferent routes of administration. PBPK predictions can refer to various physiological or disea-se states, so this unique approach can support personalized pharmacotherapy and drug/do-se/dosing regimen selection in different patient populations or individual patients (2). 
Although PBPK modeling can rely solely on the in silico generated data regarding drug’s properties (i.e., predicted based on the chemical structure of a drug), the prediction accuracy can be significantly improved with experimentally obtained input values. Therefore, any improvement in experimental drug characterization methods will inevitably lead to more reliable PBPK predictions. 
To illustrate the concept and implementation of PBPK modeling, this presentation will provide basic information on the structure of a PBPK model, and emphasis will be placed on case studies describing the interplay between drug-specific and physiologically relevant parameters that determine drug performance in vivo. Selected examples will be used to demonstrate how PBPK predictions can be used in conjunction with in vitro data on drug properties to answer clinically relevant questions, such as selecting appropriate drug therapy in bariatric patients, and assessing the impact of changes in gastric pH resulting from impaired gastric secretion or co-administration of proton pump inhibitors on drug dissolution, potential gastrointestinal precipitation and concomitant oral absorption.
PB  - International Association of Physical Chemists
C3  - 10th IAPC Meeting Tenth World Conference on Physico-Chemical Methods in Drug Discovery & Sixth World Conference on ADMET and DMPK Belgrade, Serbia, September 4-6
T1  - Highlight on the benefits of PBPK modeling: A link between drug properties and its in vivo performance
SP  - 20
EP  - 20
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5008
ER  - 

@conference{
author = "Cvijić, Sandra",
year = "2023",
abstract = "Physiologically based pharmacokinetic (PBPK) modeling or more recently also known as physiologically based biopharmaceutics modeling (PBBM) is a computer-aided (in silico) biopharmaceutical tool, designed to mechanistically describe bioperformance of a drug and predict its absorption and systemic availability. PBPK/PBBM was quickly adopted by pharmaceutical companies and medical regulatory agencies, its scope has expanded over the years, and nowadays PBPK/PBBM represents an essential tool in various phases of drug and formulation development (1). 
A major advantage of PBPK modeling over traditional in vitro and preclinical animal studies is the ability to link the physicochemical properties of a drug to its dissolution, absorption and disposition in a target patient or population, taking into account specific physiological conditions. This is accomplished through linked differential equations that describe simulta-neous or sequential dynamic processes that a drug undergoes in the body following dif-ferent routes of administration. PBPK predictions can refer to various physiological or disea-se states, so this unique approach can support personalized pharmacotherapy and drug/do-se/dosing regimen selection in different patient populations or individual patients (2). 
Although PBPK modeling can rely solely on the in silico generated data regarding drug’s properties (i.e., predicted based on the chemical structure of a drug), the prediction accuracy can be significantly improved with experimentally obtained input values. Therefore, any improvement in experimental drug characterization methods will inevitably lead to more reliable PBPK predictions. 
To illustrate the concept and implementation of PBPK modeling, this presentation will provide basic information on the structure of a PBPK model, and emphasis will be placed on case studies describing the interplay between drug-specific and physiologically relevant parameters that determine drug performance in vivo. Selected examples will be used to demonstrate how PBPK predictions can be used in conjunction with in vitro data on drug properties to answer clinically relevant questions, such as selecting appropriate drug therapy in bariatric patients, and assessing the impact of changes in gastric pH resulting from impaired gastric secretion or co-administration of proton pump inhibitors on drug dissolution, potential gastrointestinal precipitation and concomitant oral absorption.",
publisher = "International Association of Physical Chemists",
journal = "10th IAPC Meeting Tenth World Conference on Physico-Chemical Methods in Drug Discovery & Sixth World Conference on ADMET and DMPK Belgrade, Serbia, September 4-6",
title = "Highlight on the benefits of PBPK modeling: A link between drug properties and its in vivo performance",
pages = "20-20",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5008"
}

Cvijić, S.. (2023). Highlight on the benefits of PBPK modeling: A link between drug properties and its in vivo performance. in 10th IAPC Meeting Tenth World Conference on Physico-Chemical Methods in Drug Discovery & Sixth World Conference on ADMET and DMPK Belgrade, Serbia, September 4-6
International Association of Physical Chemists., 20-20.
https://hdl.handle.net/21.15107/rcub_farfar_5008

Cvijić S. Highlight on the benefits of PBPK modeling: A link between drug properties and its in vivo performance. in 10th IAPC Meeting Tenth World Conference on Physico-Chemical Methods in Drug Discovery & Sixth World Conference on ADMET and DMPK Belgrade, Serbia, September 4-6. 2023;:20-20.
https://hdl.handle.net/21.15107/rcub_farfar_5008 .

Cvijić, Sandra, "Highlight on the benefits of PBPK modeling: A link between drug properties and its in vivo performance" in 10th IAPC Meeting Tenth World Conference on Physico-Chemical Methods in Drug Discovery & Sixth World Conference on ADMET and DMPK Belgrade, Serbia, September 4-6 (2023):20-20,
https://hdl.handle.net/21.15107/rcub_farfar_5008 .

TY  - JOUR
AU  - Shi, Changzhi
AU  - Ignjatović, Jelisaveta
AU  - Wang, Junwei
AU  - Guo, Yi
AU  - Zhang, Li
AU  - Cvijić, Sandra
AU  - Cun, Dongmei
AU  - Yang, Mingshi
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4291
AB  - Respiratory antibiotics have been proven clinically beneficial for the treatment of severe lung infections such as Pseudomonas aeruginosa. Maintaining a high local concentration of inhaled antibiotics for an extended time in the lung is crucial to ensure an adequate antimicrobial efficiency. In this study, we aim to investigate whether an extended exposure of ciprofloxacin (CIP), a model fluoroquinolone drug, in the lung epithelial lining fluid (ELF) could be achieved via a controlled-release formulation strategy. CIP solutions were intratracheally instilled to the rat lungs at 3 different rates, i.e., T0h (fast), T2h (medium), and T4h (slow), to mimic different release profiles of inhaled CIP formulations in the lung. Subsequently, the concentration-time profiles of CIP in the plasma and the lung ELF were obtained, respectively, to determine topical exposure index (ELF-Plasma AUC Ratio, EPR). The in silico PBPK model, validated based on the in vivo data, was used to identify the key factors that influence the disposition of CIP in the plasma and lungs. The medium and slow rates groups exhibited much higher EPR than that fast instillation group. The ELF AUC of the medium and slow instillation groups were about 200 times higher than their plasma AUC. In contrast, the ELF AUC of the fast instillation group was only about 20 times higher than the plasma AUC. The generated whole-body PBPK rat model, validated by comparison with the in vivo data, revealed that drug pulmonary absorption rate was the key factor that determined pulmonary absorption of CIP. This study suggests that controlled CIP release from inhaled formulations may extend the exposure of CIP in the ELF post pulmonary administration. It also demonstrates that combining the proposed intratracheal installation model and in silico PBPK model is a useful approach to identify the key factors that influence the absorption and disposition of inhaled medicine.
PB  - Elsevier B.V.
T2  - Chinese Chemical Letters
T1  - Evaluating the pharmacokinetics of intrapulmonary administered ciprofloxacin solution for respiratory infections using in vivo and in silico PBPK rat model studies
VL  - 34
IS  - 1
DO  - 10.1016/j.cclet.2022.04.061
ER  - 

@article{
author = "Shi, Changzhi and Ignjatović, Jelisaveta and Wang, Junwei and Guo, Yi and Zhang, Li and Cvijić, Sandra and Cun, Dongmei and Yang, Mingshi",
year = "2023",
abstract = "Respiratory antibiotics have been proven clinically beneficial for the treatment of severe lung infections such as Pseudomonas aeruginosa. Maintaining a high local concentration of inhaled antibiotics for an extended time in the lung is crucial to ensure an adequate antimicrobial efficiency. In this study, we aim to investigate whether an extended exposure of ciprofloxacin (CIP), a model fluoroquinolone drug, in the lung epithelial lining fluid (ELF) could be achieved via a controlled-release formulation strategy. CIP solutions were intratracheally instilled to the rat lungs at 3 different rates, i.e., T0h (fast), T2h (medium), and T4h (slow), to mimic different release profiles of inhaled CIP formulations in the lung. Subsequently, the concentration-time profiles of CIP in the plasma and the lung ELF were obtained, respectively, to determine topical exposure index (ELF-Plasma AUC Ratio, EPR). The in silico PBPK model, validated based on the in vivo data, was used to identify the key factors that influence the disposition of CIP in the plasma and lungs. The medium and slow rates groups exhibited much higher EPR than that fast instillation group. The ELF AUC of the medium and slow instillation groups were about 200 times higher than their plasma AUC. In contrast, the ELF AUC of the fast instillation group was only about 20 times higher than the plasma AUC. The generated whole-body PBPK rat model, validated by comparison with the in vivo data, revealed that drug pulmonary absorption rate was the key factor that determined pulmonary absorption of CIP. This study suggests that controlled CIP release from inhaled formulations may extend the exposure of CIP in the ELF post pulmonary administration. It also demonstrates that combining the proposed intratracheal installation model and in silico PBPK model is a useful approach to identify the key factors that influence the absorption and disposition of inhaled medicine.",
publisher = "Elsevier B.V.",
journal = "Chinese Chemical Letters",
title = "Evaluating the pharmacokinetics of intrapulmonary administered ciprofloxacin solution for respiratory infections using in vivo and in silico PBPK rat model studies",
volume = "34",
number = "1",
doi = "10.1016/j.cclet.2022.04.061"
}

Shi, C., Ignjatović, J., Wang, J., Guo, Y., Zhang, L., Cvijić, S., Cun, D.,& Yang, M.. (2023). Evaluating the pharmacokinetics of intrapulmonary administered ciprofloxacin solution for respiratory infections using in vivo and in silico PBPK rat model studies. in Chinese Chemical Letters
Elsevier B.V.., 34(1).
https://doi.org/10.1016/j.cclet.2022.04.061

Shi C, Ignjatović J, Wang J, Guo Y, Zhang L, Cvijić S, Cun D, Yang M. Evaluating the pharmacokinetics of intrapulmonary administered ciprofloxacin solution for respiratory infections using in vivo and in silico PBPK rat model studies. in Chinese Chemical Letters. 2023;34(1).
doi:10.1016/j.cclet.2022.04.061 .

Shi, Changzhi, Ignjatović, Jelisaveta, Wang, Junwei, Guo, Yi, Zhang, Li, Cvijić, Sandra, Cun, Dongmei, Yang, Mingshi, "Evaluating the pharmacokinetics of intrapulmonary administered ciprofloxacin solution for respiratory infections using in vivo and in silico PBPK rat model studies" in Chinese Chemical Letters, 34, no. 1 (2023),
https://doi.org/10.1016/j.cclet.2022.04.061 . .

TY  - JOUR
AU  - Marković, Milica
AU  - Zur, Moran
AU  - Garsiani, Sapir
AU  - Porat, Daniel
AU  - Cvijić, Sandra
AU  - Amidon, Gordon L.
AU  - Dahan, Arik
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4194
AB  - The purpose of this study was to evaluate mechanisms behind the intestinal permeability of minoxidil, with special emphasis on paracellular transport, and elucidate the suitability of minoxidil to be a reference drug for Biopharmaceutics Classification System (BCS). The permeability of minoxidil (vs. metoprolol) was evaluated in-silico, in-vitro using both the PAMPA assay and across Caco-2 cell monolayers, as well as in-vivo in rats throughout the entire intestine. The permeability was studied in conditions that represent the different segments of the small intestine: upper jejunum (pH 6.5), mid small intestine (pH 7.0), distal ileum (pH 7.5), and colon (pH 6.5). Since we aimed to investigate the paracellular transport of minoxidil, we have also examined its permeability in the presence of quercetin (250 μM), which closes the tight junctions, and sodium decanoate (10 mM), which opens the tight junctions. While metoprolol demonstrated segmental-dependent rat and PAMPA permeability, with higher permeability in higher pH regions, the permeability of minoxidil was pH-independent. Minoxidil PAMPA permeability was significantly lower than its rat permeability, indicating a potential significant role of the paracellular route. In rat intestinal perfusion studies, and across Caco-2 monolayers, tight junction modifiers significantly affected minoxidil permeability; while the presence of quercetin caused decreased permeability, the presence of sodium decanoate caused an increase in minoxidil permeability. In accordance with these in-vitro and in-vivo results, in-silico simulations indicated that approximatelly 15% of minoxidil dose is absorbed paracellularly, mainly in the proximal parts of the intestine. The results of this study indicate that paracellular transport plays a significant role in the intestinal permeability of minoxidil following oral administration. Since this permeation route may lead to higher variability in comparison to transcellular, these findings diminish the suitability of minoxidil to serve as the low/high BSC permeability class benchmark.
PB  - MDPI
T2  - Pharmaceutics
T1  - The Role of Paracellular Transport in the Intestinal Absorption and Biopharmaceutical Characterization of Minoxidil
VL  - 14
IS  - 7
DO  - 10.3390/pharmaceutics14071360
ER  - 

@article{
author = "Marković, Milica and Zur, Moran and Garsiani, Sapir and Porat, Daniel and Cvijić, Sandra and Amidon, Gordon L. and Dahan, Arik",
year = "2022",
abstract = "The purpose of this study was to evaluate mechanisms behind the intestinal permeability of minoxidil, with special emphasis on paracellular transport, and elucidate the suitability of minoxidil to be a reference drug for Biopharmaceutics Classification System (BCS). The permeability of minoxidil (vs. metoprolol) was evaluated in-silico, in-vitro using both the PAMPA assay and across Caco-2 cell monolayers, as well as in-vivo in rats throughout the entire intestine. The permeability was studied in conditions that represent the different segments of the small intestine: upper jejunum (pH 6.5), mid small intestine (pH 7.0), distal ileum (pH 7.5), and colon (pH 6.5). Since we aimed to investigate the paracellular transport of minoxidil, we have also examined its permeability in the presence of quercetin (250 μM), which closes the tight junctions, and sodium decanoate (10 mM), which opens the tight junctions. While metoprolol demonstrated segmental-dependent rat and PAMPA permeability, with higher permeability in higher pH regions, the permeability of minoxidil was pH-independent. Minoxidil PAMPA permeability was significantly lower than its rat permeability, indicating a potential significant role of the paracellular route. In rat intestinal perfusion studies, and across Caco-2 monolayers, tight junction modifiers significantly affected minoxidil permeability; while the presence of quercetin caused decreased permeability, the presence of sodium decanoate caused an increase in minoxidil permeability. In accordance with these in-vitro and in-vivo results, in-silico simulations indicated that approximatelly 15% of minoxidil dose is absorbed paracellularly, mainly in the proximal parts of the intestine. The results of this study indicate that paracellular transport plays a significant role in the intestinal permeability of minoxidil following oral administration. Since this permeation route may lead to higher variability in comparison to transcellular, these findings diminish the suitability of minoxidil to serve as the low/high BSC permeability class benchmark.",
publisher = "MDPI",
journal = "Pharmaceutics",
title = "The Role of Paracellular Transport in the Intestinal Absorption and Biopharmaceutical Characterization of Minoxidil",
volume = "14",
number = "7",
doi = "10.3390/pharmaceutics14071360"
}

Marković, M., Zur, M., Garsiani, S., Porat, D., Cvijić, S., Amidon, G. L.,& Dahan, A.. (2022). The Role of Paracellular Transport in the Intestinal Absorption and Biopharmaceutical Characterization of Minoxidil. in Pharmaceutics
MDPI., 14(7).
https://doi.org/10.3390/pharmaceutics14071360

Marković M, Zur M, Garsiani S, Porat D, Cvijić S, Amidon GL, Dahan A. The Role of Paracellular Transport in the Intestinal Absorption and Biopharmaceutical Characterization of Minoxidil. in Pharmaceutics. 2022;14(7).
doi:10.3390/pharmaceutics14071360 .

Marković, Milica, Zur, Moran, Garsiani, Sapir, Porat, Daniel, Cvijić, Sandra, Amidon, Gordon L., Dahan, Arik, "The Role of Paracellular Transport in the Intestinal Absorption and Biopharmaceutical Characterization of Minoxidil" in Pharmaceutics, 14, no. 7 (2022),
https://doi.org/10.3390/pharmaceutics14071360 . .

TY  - JOUR
AU  - Aleksić, Ivana
AU  - Glišić, Teodora
AU  - Cvijić, Sandra
AU  - Parojčić, Jelena
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4244
AB  - Liquisolid systems represent an emerging approach in the preparation of solid dosage forms with liquid lipophilic drug or poorly water-soluble drug solution/suspension in suitable liquid vehicle. This study addresses the lack of data regarding the compaction behavior of liquisolid systems, with the aim to investigate the influence of liquid load, carrier to coating ratio, carrier type (microcrystalline cellulose vs. spray dried calcium hydrogen phosphate, anhydrous (Fujicalin ® )) on flowability and compaction properties of liquisolid systems and to determine the optimum liquid loads. Liquisolid admixtures with Fujicalin® showed notably better flowability than those with microcrystalline cellulose. An increase in carrier to coating ratio led to enhanced flowability of the admixtures. Compacts with Fujicalin® had good mechanical properties up to 24.7% liquid, while those with microcrystalline cellulose had acceptable mechanical strength up to 16.2% liquid. Liquisolid systems with Fujicalin® showed similar tabletability profiles as those with microcrystalline cellulose, despite having higher liquid content. The ejection stress values indicated that the addition of lubricant might be needed in the case of liquisolid systems with Fujicalin ® . Superior properties of Fujicalin ® as a carrier for liquisolid tablets were revealed, and dynamic compaction analysis was found to be a valuable tool for the assessment of compaction behavior of liquisolid systems.
AB  - Tečno-čvrsti sistemi predstavljaju novi pristup izradi čvrstih farmaceutskih oblika koji sadrže tečnu lipofilnu lekovitu supstancu ili rastvor/suspenziju slabo rastvorljive lekovite supstance u pogodnom vehikulumu. Imajući u vidu nedostatak literaturnih podataka o ponašanju tečno-čvrstih sistema pri kompresiji, cilj ovog istraživanja je ispitivanje uticaja opterećenja tečnošću, odnosa nosača i sredstva za oblaganje, kao i vrste nosača (mikrokristalna celuloza i bezvodni kalcijum-hidrogenfosfat sušen raspršivanjem (Fujicalin ® )) na protočnost i svojstva tečno-čvrstih sistema pri kompresiji, kao i određivanje optimalnog opterećenja tečnošću. Tečno- čvrste smeše sa Fujicalin ® -om su pokazale znatno bolju protočnost nego smeše sa mikrokristalnom celulozom. Uočeno je da se sa povećanjem odnosa nosača i sredstva za oblaganje poboljšava protočnost smeša. Kompakti sa Fujicalin ® -om su imali dobra mehanička svojstva do udela od 24,7% tečnosti, a kompakti sa mikrokristalnom celulozom do udela od 16,2% tečnosti. Tečno-čvrsti sistemi sa Fujicalin ® -om su pokazali slične profile tabletabilnosti onim sa mikrokristalnom celulozom, uprkos tome što sadrže znatno veći udeo tečnosti. Vrednosti pritiska potrebnog za izbacivanje kompakta iz matrice ukazuju da bi dodatak lubrikansa mogao biti potreban u slučaju tečno-čvrstih sistema sa Fujicalin ® -om. Dobijeni rezultati ukazuju na superiorna svojstva Fujicalin ® -a kao nosača u tečno-čvrstim tabletama, a dinamička analiza kompakcije može predstavljati koristan alat za procenu ponašanja tečno-čvrstih sistema pri kompresiji.
PB  - Pharmaceutical Association of Serbia
T2  - Arhiv za farmaciju
T1  - Liquisolid systems: Evaluation of the influence of formulation variables on the optimum liquid load
T1  - Tečno-čvrsti sistemi: Ispitivanje uticaja faktora formulacije na optimalno opterećenje tečnošću
VL  - 72
IS  - 1
SP  - 61
EP  - 76
DO  - 10.5937/arhfarm72-33130
ER  - 

@article{
author = "Aleksić, Ivana and Glišić, Teodora and Cvijić, Sandra and Parojčić, Jelena",
year = "2022",
abstract = "Liquisolid systems represent an emerging approach in the preparation of solid dosage forms with liquid lipophilic drug or poorly water-soluble drug solution/suspension in suitable liquid vehicle. This study addresses the lack of data regarding the compaction behavior of liquisolid systems, with the aim to investigate the influence of liquid load, carrier to coating ratio, carrier type (microcrystalline cellulose vs. spray dried calcium hydrogen phosphate, anhydrous (Fujicalin ® )) on flowability and compaction properties of liquisolid systems and to determine the optimum liquid loads. Liquisolid admixtures with Fujicalin® showed notably better flowability than those with microcrystalline cellulose. An increase in carrier to coating ratio led to enhanced flowability of the admixtures. Compacts with Fujicalin® had good mechanical properties up to 24.7% liquid, while those with microcrystalline cellulose had acceptable mechanical strength up to 16.2% liquid. Liquisolid systems with Fujicalin® showed similar tabletability profiles as those with microcrystalline cellulose, despite having higher liquid content. The ejection stress values indicated that the addition of lubricant might be needed in the case of liquisolid systems with Fujicalin ® . Superior properties of Fujicalin ® as a carrier for liquisolid tablets were revealed, and dynamic compaction analysis was found to be a valuable tool for the assessment of compaction behavior of liquisolid systems., Tečno-čvrsti sistemi predstavljaju novi pristup izradi čvrstih farmaceutskih oblika koji sadrže tečnu lipofilnu lekovitu supstancu ili rastvor/suspenziju slabo rastvorljive lekovite supstance u pogodnom vehikulumu. Imajući u vidu nedostatak literaturnih podataka o ponašanju tečno-čvrstih sistema pri kompresiji, cilj ovog istraživanja je ispitivanje uticaja opterećenja tečnošću, odnosa nosača i sredstva za oblaganje, kao i vrste nosača (mikrokristalna celuloza i bezvodni kalcijum-hidrogenfosfat sušen raspršivanjem (Fujicalin ® )) na protočnost i svojstva tečno-čvrstih sistema pri kompresiji, kao i određivanje optimalnog opterećenja tečnošću. Tečno- čvrste smeše sa Fujicalin ® -om su pokazale znatno bolju protočnost nego smeše sa mikrokristalnom celulozom. Uočeno je da se sa povećanjem odnosa nosača i sredstva za oblaganje poboljšava protočnost smeša. Kompakti sa Fujicalin ® -om su imali dobra mehanička svojstva do udela od 24,7% tečnosti, a kompakti sa mikrokristalnom celulozom do udela od 16,2% tečnosti. Tečno-čvrsti sistemi sa Fujicalin ® -om su pokazali slične profile tabletabilnosti onim sa mikrokristalnom celulozom, uprkos tome što sadrže znatno veći udeo tečnosti. Vrednosti pritiska potrebnog za izbacivanje kompakta iz matrice ukazuju da bi dodatak lubrikansa mogao biti potreban u slučaju tečno-čvrstih sistema sa Fujicalin ® -om. Dobijeni rezultati ukazuju na superiorna svojstva Fujicalin ® -a kao nosača u tečno-čvrstim tabletama, a dinamička analiza kompakcije može predstavljati koristan alat za procenu ponašanja tečno-čvrstih sistema pri kompresiji.",
publisher = "Pharmaceutical Association of Serbia",
journal = "Arhiv za farmaciju",
title = "Liquisolid systems: Evaluation of the influence of formulation variables on the optimum liquid load, Tečno-čvrsti sistemi: Ispitivanje uticaja faktora formulacije na optimalno opterećenje tečnošću",
volume = "72",
number = "1",
pages = "61-76",
doi = "10.5937/arhfarm72-33130"
}

Aleksić, I., Glišić, T., Cvijić, S.,& Parojčić, J.. (2022). Liquisolid systems: Evaluation of the influence of formulation variables on the optimum liquid load. in Arhiv za farmaciju
Pharmaceutical Association of Serbia., 72(1), 61-76.
https://doi.org/10.5937/arhfarm72-33130

Aleksić I, Glišić T, Cvijić S, Parojčić J. Liquisolid systems: Evaluation of the influence of formulation variables on the optimum liquid load. in Arhiv za farmaciju. 2022;72(1):61-76.
doi:10.5937/arhfarm72-33130 .

Aleksić, Ivana, Glišić, Teodora, Cvijić, Sandra, Parojčić, Jelena, "Liquisolid systems: Evaluation of the influence of formulation variables on the optimum liquid load" in Arhiv za farmaciju, 72, no. 1 (2022):61-76,
https://doi.org/10.5937/arhfarm72-33130 . .

TY  - JOUR
AU  - Šušteršič, Tijana
AU  - Bodić, Aleksandar
AU  - Ignjatović, Jelisaveta
AU  - Cvijić, Sandra
AU  - Ibrić, Svetlana
AU  - Filipović, Nenad
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4367
AB  - The development of novel dry powders for dry powder inhalers (DPIs) requires the in vitro assessment of DPI aerodynamic performance. As a potential complementary method, in silico numerical simulations can provide additional information about the mechanisms that guide the particles and their behavior inside DPIs. The aim of this study was to apply computational fluid dynamics (CFDs) coupled with a discrete phase model (DPM) to describe the forces and particle trajectories inside the RS01® as a model DPI device. The methodology included standard fluid flow equations but also additional equations for the particle sticking mechanism, as well as particle behavior after contacting the DPI wall surface, including the particle detachment process. The results show that the coefficient of restitution between the particle and the impact surface does not have a high impact on the results, meaning that all tested combinations gave similar output efficiencies and particle behaviors. No sliding or rolling mechanisms were observed for the particle detachment process, meaning that simple bouncing off or deposition particle behavior is present inside DPIs. The developed methodology can serve as a basis for the additional understanding of the particles’ behavior inside DPIs, which is not possible using only in vitro experiments; this implies the possibility of increasing the efficiency of DPIs.
PB  - MDPI
T2  - Pharmaceutics
T1  - Numerical Modeling of Particle Dynamics Inside a Dry Powder Inhaler
VL  - 14
IS  - 12
DO  - 10.3390/pharmaceutics14122591
ER  - 

@article{
author = "Šušteršič, Tijana and Bodić, Aleksandar and Ignjatović, Jelisaveta and Cvijić, Sandra and Ibrić, Svetlana and Filipović, Nenad",
year = "2022",
abstract = "The development of novel dry powders for dry powder inhalers (DPIs) requires the in vitro assessment of DPI aerodynamic performance. As a potential complementary method, in silico numerical simulations can provide additional information about the mechanisms that guide the particles and their behavior inside DPIs. The aim of this study was to apply computational fluid dynamics (CFDs) coupled with a discrete phase model (DPM) to describe the forces and particle trajectories inside the RS01® as a model DPI device. The methodology included standard fluid flow equations but also additional equations for the particle sticking mechanism, as well as particle behavior after contacting the DPI wall surface, including the particle detachment process. The results show that the coefficient of restitution between the particle and the impact surface does not have a high impact on the results, meaning that all tested combinations gave similar output efficiencies and particle behaviors. No sliding or rolling mechanisms were observed for the particle detachment process, meaning that simple bouncing off or deposition particle behavior is present inside DPIs. The developed methodology can serve as a basis for the additional understanding of the particles’ behavior inside DPIs, which is not possible using only in vitro experiments; this implies the possibility of increasing the efficiency of DPIs.",
publisher = "MDPI",
journal = "Pharmaceutics",
title = "Numerical Modeling of Particle Dynamics Inside a Dry Powder Inhaler",
volume = "14",
number = "12",
doi = "10.3390/pharmaceutics14122591"
}

Šušteršič, T., Bodić, A., Ignjatović, J., Cvijić, S., Ibrić, S.,& Filipović, N.. (2022). Numerical Modeling of Particle Dynamics Inside a Dry Powder Inhaler. in Pharmaceutics
MDPI., 14(12).
https://doi.org/10.3390/pharmaceutics14122591

Šušteršič T, Bodić A, Ignjatović J, Cvijić S, Ibrić S, Filipović N. Numerical Modeling of Particle Dynamics Inside a Dry Powder Inhaler. in Pharmaceutics. 2022;14(12).
doi:10.3390/pharmaceutics14122591 .

Šušteršič, Tijana, Bodić, Aleksandar, Ignjatović, Jelisaveta, Cvijić, Sandra, Ibrić, Svetlana, Filipović, Nenad, "Numerical Modeling of Particle Dynamics Inside a Dry Powder Inhaler" in Pharmaceutics, 14, no. 12 (2022),
https://doi.org/10.3390/pharmaceutics14122591 . .

TY  - JOUR
AU  - Porat, Daniel
AU  - Dukhno, Oleg
AU  - Vainer, Ella
AU  - Cvijić, Sandra
AU  - Dahan, Arik
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4241
AB  - Gastrointestinal anatomical/physiological changes after bariatric surgery influence variables affecting the fate of drugs after ingestion, and medication management of these patients requires a thorough and complex mechanistic analysis. The aim of this research was to study whether loratadine/desloratadine antiallergic treatment of bariatric patients is at risk of being ineffective due to impaired solubility/dissolution. The pH-depend- ent solubility of loratadine/desloratadine was studied in vitro, as well as ex vivo, in gastric content aspirated from patients before versus after bariatric surgery. Then, a biorelevant dissolution method was developed to simulate the gastric conditions after sleeve gastrectomy (SG) or one-anastomosis gastric bypass (OAGB), accounting for key variables (intragastric volume, pH, and contractility), and the dissolution of loratadine/desloratadine was studied pre- versus post-surgery. Dissolution was also studied after tablet crushing or syrup ingestion, as these actions are recommended after bariatric surgery. Finally, these experimental data were implemented in a newly developed physiologically based pharmacokinetic (PBPK) model to simulate loratadine/desloratadine PK profiles pre- versus post-surgery. For both drugs, pH-dependent solubility was demonstrated, with decreased solubility at higher pH; over the pH range 1−7, loratadine solubility decreased ∼2000-fold, and desloratadine decreased ∼120-fold. Ex vivo solubility in aspirated human gastric fluid pre- versus post-surgery was in good agreement with these in vitro results and revealed that while desloratadine solubility still allows complete dissolution post-surgery, loratadine solubility post-surgery is much lower than the threshold required for the complete dissolution of the drug dose. Indeed, severely hampered loratadine dissolution was revealed, dropping from 100% pre-surgery to only 3 and 1% post-SG and post-OAGB, respectively. Tablet crushing did not increase loratadine dissolution in any post-bariatric condition, nor did loratadine syrup in post-OAGB (pH 7) media, while in post-laparoscopic SG conditions (pH 5), the syrup provided partial improvement of up to 40% dissolution. Desloratadine exhibited quick and complete dissolution across all pre-/post-surgery conditions. PBPK simulations revealed pronounced impaired absorption of loratadine post- surgery, with 84−88% decreased Cmax, 28−36% decreased Fa, and 24−31% decreased overall bioavailability, depending on the type of bariatric procedure. Desloratadine absorption remained unchanged post-surgery. We propose that desloratadine should be preferred over loratadine in bariatric patients, and as loratadine is an over-the-counter medication, antiallergic therapy after bariatric surgery requires special attention by patients and clinicians alike. This mechanistic approach that reveals potential post-surgery complexity, and at the same time provides adequate substitutions, may contribute to better pharmacotherapy and overall patient care after bariatric surgery.
PB  - American Chemical Society
T2  - Molecular Pharmaceutics
T1  - Antiallergic Treatment of Bariatric Patients: Potentially Hampered Solubility/Dissolution and Bioavailability of Loratadine, but Not Desloratadine, Post-Bariatric Surgery
VL  - 19
IS  - 8
SP  - 2922
EP  - 2936
DO  - 10.1021/acs.molpharmaceut.2c00292
ER  - 

@article{
author = "Porat, Daniel and Dukhno, Oleg and Vainer, Ella and Cvijić, Sandra and Dahan, Arik",
year = "2022",
abstract = "Gastrointestinal anatomical/physiological changes after bariatric surgery influence variables affecting the fate of drugs after ingestion, and medication management of these patients requires a thorough and complex mechanistic analysis. The aim of this research was to study whether loratadine/desloratadine antiallergic treatment of bariatric patients is at risk of being ineffective due to impaired solubility/dissolution. The pH-depend- ent solubility of loratadine/desloratadine was studied in vitro, as well as ex vivo, in gastric content aspirated from patients before versus after bariatric surgery. Then, a biorelevant dissolution method was developed to simulate the gastric conditions after sleeve gastrectomy (SG) or one-anastomosis gastric bypass (OAGB), accounting for key variables (intragastric volume, pH, and contractility), and the dissolution of loratadine/desloratadine was studied pre- versus post-surgery. Dissolution was also studied after tablet crushing or syrup ingestion, as these actions are recommended after bariatric surgery. Finally, these experimental data were implemented in a newly developed physiologically based pharmacokinetic (PBPK) model to simulate loratadine/desloratadine PK profiles pre- versus post-surgery. For both drugs, pH-dependent solubility was demonstrated, with decreased solubility at higher pH; over the pH range 1−7, loratadine solubility decreased ∼2000-fold, and desloratadine decreased ∼120-fold. Ex vivo solubility in aspirated human gastric fluid pre- versus post-surgery was in good agreement with these in vitro results and revealed that while desloratadine solubility still allows complete dissolution post-surgery, loratadine solubility post-surgery is much lower than the threshold required for the complete dissolution of the drug dose. Indeed, severely hampered loratadine dissolution was revealed, dropping from 100% pre-surgery to only 3 and 1% post-SG and post-OAGB, respectively. Tablet crushing did not increase loratadine dissolution in any post-bariatric condition, nor did loratadine syrup in post-OAGB (pH 7) media, while in post-laparoscopic SG conditions (pH 5), the syrup provided partial improvement of up to 40% dissolution. Desloratadine exhibited quick and complete dissolution across all pre-/post-surgery conditions. PBPK simulations revealed pronounced impaired absorption of loratadine post- surgery, with 84−88% decreased Cmax, 28−36% decreased Fa, and 24−31% decreased overall bioavailability, depending on the type of bariatric procedure. Desloratadine absorption remained unchanged post-surgery. We propose that desloratadine should be preferred over loratadine in bariatric patients, and as loratadine is an over-the-counter medication, antiallergic therapy after bariatric surgery requires special attention by patients and clinicians alike. This mechanistic approach that reveals potential post-surgery complexity, and at the same time provides adequate substitutions, may contribute to better pharmacotherapy and overall patient care after bariatric surgery.",
publisher = "American Chemical Society",
journal = "Molecular Pharmaceutics",
title = "Antiallergic Treatment of Bariatric Patients: Potentially Hampered Solubility/Dissolution and Bioavailability of Loratadine, but Not Desloratadine, Post-Bariatric Surgery",
volume = "19",
number = "8",
pages = "2922-2936",
doi = "10.1021/acs.molpharmaceut.2c00292"
}

Porat, D., Dukhno, O., Vainer, E., Cvijić, S.,& Dahan, A.. (2022). Antiallergic Treatment of Bariatric Patients: Potentially Hampered Solubility/Dissolution and Bioavailability of Loratadine, but Not Desloratadine, Post-Bariatric Surgery. in Molecular Pharmaceutics
American Chemical Society., 19(8), 2922-2936.
https://doi.org/10.1021/acs.molpharmaceut.2c00292

Porat D, Dukhno O, Vainer E, Cvijić S, Dahan A. Antiallergic Treatment of Bariatric Patients: Potentially Hampered Solubility/Dissolution and Bioavailability of Loratadine, but Not Desloratadine, Post-Bariatric Surgery. in Molecular Pharmaceutics. 2022;19(8):2922-2936.
doi:10.1021/acs.molpharmaceut.2c00292 .

Porat, Daniel, Dukhno, Oleg, Vainer, Ella, Cvijić, Sandra, Dahan, Arik, "Antiallergic Treatment of Bariatric Patients: Potentially Hampered Solubility/Dissolution and Bioavailability of Loratadine, but Not Desloratadine, Post-Bariatric Surgery" in Molecular Pharmaceutics, 19, no. 8 (2022):2922-2936,
https://doi.org/10.1021/acs.molpharmaceut.2c00292 . .

TY  - CONF
AU  - Ćetković, Zora
AU  - Vasiljević, Ivana
AU  - Cvijić, Sandra
AU  - Vasiljević, Dragana
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4567
AB  - Mixing selected liquid SMEDDS with polymethacrylate polymers (Eudragit ®) led to
solidification of the samples to form solid, ductile, transparent systems (1). The purpose of
this study was to define mechanical properties and long-term stability of novel simvastatin-
loaded SMEDDS-based drug delivery systems. SMEDDS-based formulations were prepared
by adding liquid SMEDDS (10% oleoyl macrogol-6 glycerides and 90% caprylocaproyl
macrogol-8 glycerides/macrogol-15-hydroxystearate, in 3 ratios: 1:1, 2:1 and 3:1) to
Eudragit ® S100 or Eudragit ® S100/Eudragit ® L100 combination (in 1:1 ratio), until
SMEDDS/polymer ratio 2:1 w/w was reached. SMEDDS-based formulations with simvastatin
(SV) were prepared by dissolving SV (5%) into liquid SMEDDS and mixing with
polymethacrylate polymers in the same ratio. Prepared formulations were evaluated in
terms of their mechanical properties and long-term stability. The results indicated that the
increase in the caprylocaproyl macrogol-8 glycerides concentration resulted in higher
penetration force (F1 S100–F3 S100 = 5.83-7.22 N and F1 SL100-F3 SL100 = 4.20-5.99 N).
However, addition of SV was negatively correlated with the hardness, i.e. samples with SV
were softer in comparison to unloaded samples. Moreover, it was noticeable that
formulations with Eudragit ® S100 had greater penetration force values compared to
formulations containing Eudragit ® S100/Eudragit ® L100. After six months of storage at
room and elevated temperature, only slight decrease in SV content (less than 5%) was
observed in these samples. This study demonstrated that novel SMEDDS-based formulations
with higher concentration of caprylocaproyl macrogol-8 glycerides and those with Eudragit ®
S100 were more robust, which may further serve as a guide for formulating tailor-made
formulations.
AB  - Mešanje odabranih tečnih samomikroemulgujućih sistema (SMEDDS) sa
kopolimerima metakrilne kiseline (Eudragit ® ) dovodi do očvršćavanja uzoraka i formiranja
čvrstih, rastegljivih, transparentnih sistema (1). Cilj ovog rada je bio ispitivanje mehaničkih
svojstva i dugotrajne stabilnosti novih lipidnih sistema sa simvastatinom (SV). Lipidne
formulacije su izrađene mešanjem tečnih SMEDDS (10% oleoil makrogol-6 glicerida i 90%
kaprilokaproil makrogol-8 glicerida/makrogol-15-hidroksistearat, u 3 odnosa: 1:1, 2:1 i 3:1)
i Eudragit ® S100 ili kombinacije Eudragit ® S100/Eudragit ® L100 (u odnosu 1:1). Odnos
SMEDDS/polimer bio je 2:1, m/m. Uzorci sa SV su izrađeni rastvaranjem SV (5%) u tečnim
SMEDDS i mešanjem sa kopolimerima metakrilne kiseline u navedenom odnosu. Sprovedena
su ispitivanja mehaničkih osobina i dugotrajne stabilnosti izrađenih lipidnih formulacija.
Rezultati su pokazali da povećanje koncentracije kaprilokaproil makrogol-8 glicerida dovodi
do povećanja vrednosti sile penetracije (F1 S100–F3 S100 = 5,83-7,22 N i F1 SL100-F3
SL100 = 4,20-5,99 N). Uzorci sa SV su bili mekši, u poređenju sa uzorcima bez lekovite
supstance. Takođe, uočeno je da uzorci sa polimerom Eudragit ® S100 imaju već e vrednosti
sile penetracije, u poređenju sa formulacijama koje sadrže kombinaciju Eudragit ®
S100/Eudragit ® L100. Posle šest meseci skladištenja uzoraka na sobnoj i povišenoj
temperaturi, sadržaj SV je neznatno smanjen (manje od 5%). Ova studija je pokazala da nove
lipidne formulacije izrađene sa većom koncentracijom kaprilokaproil makrogol-8 glicerida i
sa Eudragit ® S100 polimerom imaju veće vrednosti sile penetracije i prihvatljivu dugotrajnu
stabilnost, što je od značaja za razvoj lipidnih formulacija željenih karakteristika.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Mechanical properties and long-term stability of novel lipid formulations with simvastatin
T1  - Mehanička svojstva i dugotrajna stabilnost novih lipidnih formulacija sa simvastatinom
VL  - 72
IS  - 4 suplement
SP  - S396
EP  - S397
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4567
ER  - 

@conference{
author = "Ćetković, Zora and Vasiljević, Ivana and Cvijić, Sandra and Vasiljević, Dragana",
year = "2022",
abstract = "Mixing selected liquid SMEDDS with polymethacrylate polymers (Eudragit ®) led to
solidification of the samples to form solid, ductile, transparent systems (1). The purpose of
this study was to define mechanical properties and long-term stability of novel simvastatin-
loaded SMEDDS-based drug delivery systems. SMEDDS-based formulations were prepared
by adding liquid SMEDDS (10% oleoyl macrogol-6 glycerides and 90% caprylocaproyl
macrogol-8 glycerides/macrogol-15-hydroxystearate, in 3 ratios: 1:1, 2:1 and 3:1) to
Eudragit ® S100 or Eudragit ® S100/Eudragit ® L100 combination (in 1:1 ratio), until
SMEDDS/polymer ratio 2:1 w/w was reached. SMEDDS-based formulations with simvastatin
(SV) were prepared by dissolving SV (5%) into liquid SMEDDS and mixing with
polymethacrylate polymers in the same ratio. Prepared formulations were evaluated in
terms of their mechanical properties and long-term stability. The results indicated that the
increase in the caprylocaproyl macrogol-8 glycerides concentration resulted in higher
penetration force (F1 S100–F3 S100 = 5.83-7.22 N and F1 SL100-F3 SL100 = 4.20-5.99 N).
However, addition of SV was negatively correlated with the hardness, i.e. samples with SV
were softer in comparison to unloaded samples. Moreover, it was noticeable that
formulations with Eudragit ® S100 had greater penetration force values compared to
formulations containing Eudragit ® S100/Eudragit ® L100. After six months of storage at
room and elevated temperature, only slight decrease in SV content (less than 5%) was
observed in these samples. This study demonstrated that novel SMEDDS-based formulations
with higher concentration of caprylocaproyl macrogol-8 glycerides and those with Eudragit ®
S100 were more robust, which may further serve as a guide for formulating tailor-made
formulations., Mešanje odabranih tečnih samomikroemulgujućih sistema (SMEDDS) sa
kopolimerima metakrilne kiseline (Eudragit ® ) dovodi do očvršćavanja uzoraka i formiranja
čvrstih, rastegljivih, transparentnih sistema (1). Cilj ovog rada je bio ispitivanje mehaničkih
svojstva i dugotrajne stabilnosti novih lipidnih sistema sa simvastatinom (SV). Lipidne
formulacije su izrađene mešanjem tečnih SMEDDS (10% oleoil makrogol-6 glicerida i 90%
kaprilokaproil makrogol-8 glicerida/makrogol-15-hidroksistearat, u 3 odnosa: 1:1, 2:1 i 3:1)
i Eudragit ® S100 ili kombinacije Eudragit ® S100/Eudragit ® L100 (u odnosu 1:1). Odnos
SMEDDS/polimer bio je 2:1, m/m. Uzorci sa SV su izrađeni rastvaranjem SV (5%) u tečnim
SMEDDS i mešanjem sa kopolimerima metakrilne kiseline u navedenom odnosu. Sprovedena
su ispitivanja mehaničkih osobina i dugotrajne stabilnosti izrađenih lipidnih formulacija.
Rezultati su pokazali da povećanje koncentracije kaprilokaproil makrogol-8 glicerida dovodi
do povećanja vrednosti sile penetracije (F1 S100–F3 S100 = 5,83-7,22 N i F1 SL100-F3
SL100 = 4,20-5,99 N). Uzorci sa SV su bili mekši, u poređenju sa uzorcima bez lekovite
supstance. Takođe, uočeno je da uzorci sa polimerom Eudragit ® S100 imaju već e vrednosti
sile penetracije, u poređenju sa formulacijama koje sadrže kombinaciju Eudragit ®
S100/Eudragit ® L100. Posle šest meseci skladištenja uzoraka na sobnoj i povišenoj
temperaturi, sadržaj SV je neznatno smanjen (manje od 5%). Ova studija je pokazala da nove
lipidne formulacije izrađene sa većom koncentracijom kaprilokaproil makrogol-8 glicerida i
sa Eudragit ® S100 polimerom imaju veće vrednosti sile penetracije i prihvatljivu dugotrajnu
stabilnost, što je od značaja za razvoj lipidnih formulacija željenih karakteristika.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Mechanical properties and long-term stability of novel lipid formulations with simvastatin, Mehanička svojstva i dugotrajna stabilnost novih lipidnih formulacija sa simvastatinom",
volume = "72",
number = "4 suplement",
pages = "S396-S397",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4567"
}

Ćetković, Z., Vasiljević, I., Cvijić, S.,& Vasiljević, D.. (2022). Mechanical properties and long-term stability of novel lipid formulations with simvastatin. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S396-S397.
https://hdl.handle.net/21.15107/rcub_farfar_4567

Ćetković Z, Vasiljević I, Cvijić S, Vasiljević D. Mechanical properties and long-term stability of novel lipid formulations with simvastatin. in Arhiv za farmaciju. 2022;72(4 suplement):S396-S397.
https://hdl.handle.net/21.15107/rcub_farfar_4567 .

Ćetković, Zora, Vasiljević, Ivana, Cvijić, Sandra, Vasiljević, Dragana, "Mechanical properties and long-term stability of novel lipid formulations with simvastatin" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S396-S397,
https://hdl.handle.net/21.15107/rcub_farfar_4567 .

TY  - CONF
AU  - Kurćubić, Ivana
AU  - Vajić, Una‐Jovana
AU  - Cvijić, Sandra
AU  - Crevar-Sakač, Milkica
AU  - Ibrić, Svetlana
AU  - Miloradović, Zoran
AU  - Mihailović‐Stanojević, Nevena
AU  - Ivanov, Milan
AU  - Karanović, Danijela
AU  - Jovović, Đurđica
AU  - Đuriš, Jelena
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4512
AB  - Mucoadhesive buccal films can improve drug absorption by prolonging its retention
time on the buccal mucosa (1). The aim of the study was a comparative assessment of the
hemodynamic effects and pharmacokinetics of propranolol hydrochloride (PROP) after
buccal and oral administration in spontaneously hypertensive rats. Animals were divided
into 3 groups: Group I (control) received 0.5 mL of water with a gastric tube, group II
received an immediate-release 10 mg PROP tablet via gastric tube, and group III received a
mucoadhesive 10 mg PROP buccal film. Systolic (SP) and diastolic blood pressure (DP), and
heart rate (SF) were measured in rats, and pharmacokinetic PROP parameters, Cmax, tmax,
and AUC0 → 24, were calculated by noncompartmental analysis. Mucoadhesive buccal films
showed superior degree of absorption of PROP over immediate-release tablets (AUC0 → 24:
69.64 μgh/ml versus 24.61 μgh/ml). The tmax value was significantly higher in
mucoadhesive buccal films, which indicates a prolonged PROP release and longer
therapeutic effect (71.19h versus 29.73h). There was no statistically significant difference in
Cmax values between groups II and III of rats (4.74 μg ml versus 7.11 μg ml). Mucoadhesive
buccal films provide a more pronounced and long-lasting reduction primarily of SF
(reduction of 28-51% lasting from 10 minutes to the twelfth hour of testing), but also SP and
DP (between 15-30% from the first to the sixth hour of testing) compared to immediate-
release tablets. Mucoadhesive buccal films allow bypass/reduction of the extensive hepatic
first-pass metabolism, and consequently improve the therapeutic PROP effect.
AB  - Mukoadhezivni bukalni filmovi mogu poboljšati apsorpciju lekovite supstance
produžavajuć i vreme zadržavanja lekovitog preparata na bukalnoj sluznici (1). Cilj studije je
bila komparativna procena hemodinamskih efekata i farmakokinetike propranolol-
hidrohlorida (PROP) nakon bukalne i peroralne primene kod sponatano hipertenzivnih
pacova. Spontano hipertenzivni pacovi su podeljeni u 3 grupe: I (kontrolna) grupa je dobila
0,5 mL vode gastričnom sondom, II grupa je dobila tabletu sa trenutnim oslobađanjem sa 10
mg PROP gastričnom sondom i III grupa je dobila mukoadhezivni bukalni film sa 10 mg
PROP. Filmovi su pripremljeni korišćenjem polietilenoksida, hidroksipropilmetilceluloze i
polivinilalkohola kao film-formirajućih polimera sa mukoadhezivnim svojstvima. Pacovima
su mereni sistolni (SP) i dijastolni krvni pritisak (DP), srčana frekvencija (SF), a
neprostornom farmakokinetičkom analizom izračunati su parametri PROP: Cmax, t max i
AUC0→24 . Mukoadhezivni bukalni filmovi su pokazali superiornost u odnosu na tablete sa
trenutnim oslobađanjem u pogledu stepena apsorpcije PROP (AUC 0→24 : 69,64 μgh/ml
naspram 24,61 μgh/ml). Tmax vrednost je bila značajno veća kod mukoadhezivnih bukalnih
filmova što ukazuje na produženo oslobađanje PROP i duži terapijski efekat (71,19 h
naspram 29,73 h). Između II i II grupe pacova nema statistički značajne razlike u
vrednostima Cmax (4,74 μg/ml naspram 7,11 μg/ml). Mukoadhezivni bukalni filmovi izazivaju
izraženije i dugotrajnije smanjenje pre svega SF (smanjenje od 28-51% u trajanju od 10
minuta do dvanaestog sata ispitivanja), ali i SP i DP (između 15-30% od prvog do šestog sata
ispitivanja) u odnosu na tablete sa trenutnim oslobađanjem. Pripremljeni mukoadhezivni
bukalni filmovi omogućavaju zaobilazak/smanjenje ekstenzivnog metabolizma prvog
prolaza kroz jetru i posledično poboljšavaju terapijski efekat PROP.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Effects of acute application of mucoadhesive buccal films with propranolol hydrochloride in an animal model of essential hypertension
T1  - Efekti akutne primene mukoadhezivnih bukalnih filmova sa propranolol‐hidrohloridom u animalnom modelu esencijalne hipertenzije
VL  - 72
IS  - 4 suplement
SP  - S235
EP  - S236
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4512
ER  - 

@conference{
author = "Kurćubić, Ivana and Vajić, Una‐Jovana and Cvijić, Sandra and Crevar-Sakač, Milkica and Ibrić, Svetlana and Miloradović, Zoran and Mihailović‐Stanojević, Nevena and Ivanov, Milan and Karanović, Danijela and Jovović, Đurđica and Đuriš, Jelena",
year = "2022",
abstract = "Mucoadhesive buccal films can improve drug absorption by prolonging its retention
time on the buccal mucosa (1). The aim of the study was a comparative assessment of the
hemodynamic effects and pharmacokinetics of propranolol hydrochloride (PROP) after
buccal and oral administration in spontaneously hypertensive rats. Animals were divided
into 3 groups: Group I (control) received 0.5 mL of water with a gastric tube, group II
received an immediate-release 10 mg PROP tablet via gastric tube, and group III received a
mucoadhesive 10 mg PROP buccal film. Systolic (SP) and diastolic blood pressure (DP), and
heart rate (SF) were measured in rats, and pharmacokinetic PROP parameters, Cmax, tmax,
and AUC0 → 24, were calculated by noncompartmental analysis. Mucoadhesive buccal films
showed superior degree of absorption of PROP over immediate-release tablets (AUC0 → 24:
69.64 μgh/ml versus 24.61 μgh/ml). The tmax value was significantly higher in
mucoadhesive buccal films, which indicates a prolonged PROP release and longer
therapeutic effect (71.19h versus 29.73h). There was no statistically significant difference in
Cmax values between groups II and III of rats (4.74 μg ml versus 7.11 μg ml). Mucoadhesive
buccal films provide a more pronounced and long-lasting reduction primarily of SF
(reduction of 28-51% lasting from 10 minutes to the twelfth hour of testing), but also SP and
DP (between 15-30% from the first to the sixth hour of testing) compared to immediate-
release tablets. Mucoadhesive buccal films allow bypass/reduction of the extensive hepatic
first-pass metabolism, and consequently improve the therapeutic PROP effect., Mukoadhezivni bukalni filmovi mogu poboljšati apsorpciju lekovite supstance
produžavajuć i vreme zadržavanja lekovitog preparata na bukalnoj sluznici (1). Cilj studije je
bila komparativna procena hemodinamskih efekata i farmakokinetike propranolol-
hidrohlorida (PROP) nakon bukalne i peroralne primene kod sponatano hipertenzivnih
pacova. Spontano hipertenzivni pacovi su podeljeni u 3 grupe: I (kontrolna) grupa je dobila
0,5 mL vode gastričnom sondom, II grupa je dobila tabletu sa trenutnim oslobađanjem sa 10
mg PROP gastričnom sondom i III grupa je dobila mukoadhezivni bukalni film sa 10 mg
PROP. Filmovi su pripremljeni korišćenjem polietilenoksida, hidroksipropilmetilceluloze i
polivinilalkohola kao film-formirajućih polimera sa mukoadhezivnim svojstvima. Pacovima
su mereni sistolni (SP) i dijastolni krvni pritisak (DP), srčana frekvencija (SF), a
neprostornom farmakokinetičkom analizom izračunati su parametri PROP: Cmax, t max i
AUC0→24 . Mukoadhezivni bukalni filmovi su pokazali superiornost u odnosu na tablete sa
trenutnim oslobađanjem u pogledu stepena apsorpcije PROP (AUC 0→24 : 69,64 μgh/ml
naspram 24,61 μgh/ml). Tmax vrednost je bila značajno veća kod mukoadhezivnih bukalnih
filmova što ukazuje na produženo oslobađanje PROP i duži terapijski efekat (71,19 h
naspram 29,73 h). Između II i II grupe pacova nema statistički značajne razlike u
vrednostima Cmax (4,74 μg/ml naspram 7,11 μg/ml). Mukoadhezivni bukalni filmovi izazivaju
izraženije i dugotrajnije smanjenje pre svega SF (smanjenje od 28-51% u trajanju od 10
minuta do dvanaestog sata ispitivanja), ali i SP i DP (između 15-30% od prvog do šestog sata
ispitivanja) u odnosu na tablete sa trenutnim oslobađanjem. Pripremljeni mukoadhezivni
bukalni filmovi omogućavaju zaobilazak/smanjenje ekstenzivnog metabolizma prvog
prolaza kroz jetru i posledično poboljšavaju terapijski efekat PROP.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Effects of acute application of mucoadhesive buccal films with propranolol hydrochloride in an animal model of essential hypertension, Efekti akutne primene mukoadhezivnih bukalnih filmova sa propranolol‐hidrohloridom u animalnom modelu esencijalne hipertenzije",
volume = "72",
number = "4 suplement",
pages = "S235-S236",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4512"
}

Kurćubić, I., Vajić, U., Cvijić, S., Crevar-Sakač, M., Ibrić, S., Miloradović, Z., Mihailović‐Stanojević, N., Ivanov, M., Karanović, D., Jovović, Đ.,& Đuriš, J.. (2022). Effects of acute application of mucoadhesive buccal films with propranolol hydrochloride in an animal model of essential hypertension. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S235-S236.
https://hdl.handle.net/21.15107/rcub_farfar_4512

Kurćubić I, Vajić U, Cvijić S, Crevar-Sakač M, Ibrić S, Miloradović Z, Mihailović‐Stanojević N, Ivanov M, Karanović D, Jovović Đ, Đuriš J. Effects of acute application of mucoadhesive buccal films with propranolol hydrochloride in an animal model of essential hypertension. in Arhiv za farmaciju. 2022;72(4 suplement):S235-S236.
https://hdl.handle.net/21.15107/rcub_farfar_4512 .

Kurćubić, Ivana, Vajić, Una‐Jovana, Cvijić, Sandra, Crevar-Sakač, Milkica, Ibrić, Svetlana, Miloradović, Zoran, Mihailović‐Stanojević, Nevena, Ivanov, Milan, Karanović, Danijela, Jovović, Đurđica, Đuriš, Jelena, "Effects of acute application of mucoadhesive buccal films with propranolol hydrochloride in an animal model of essential hypertension" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S235-S236,
https://hdl.handle.net/21.15107/rcub_farfar_4512 .

TY  - CONF
AU  - Cvijić, Sandra
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4455
AB  - The application of computer-based (in silico) modeling&simulation tools has become a
global trend in different areas of science, including pharmaceutical sciences. These methods
have been increasingly used in different phases of formulation development, starting with
defining a sound formulation strategy, through the selection of drug dose and optimal
formulation for clinical studies, to the prediction of drug absorption/disposition in different
populations, identification of potential drug-drug interactions, prediction of bioequivalence
study outcomes and justification of biowaivers (1). In silico tools for the prediction of drug
bioperformance incorporate the so called physiologically-based models i.e., systems of data
on physiological conditions and processes a drug undergoes in the organism, with an
adequate mathematical background to describe these processes. As such, these models allow
prediction of the expected therapeutic outcomes following drug administration, and offer a
distinctive opportunity to test hypotheses and identify the underlying mechanisms
responsible for the phenomena a drug undergoes in vivo. In other words, they act as a digital
window to “drug’s journey through the body”. Physiologically-based models have been
upgraded continuously, and relatively simple models evolved into the model-based drug
development platforms, initiating a transformational change in drug formulation
research&development. Opposed to the traditional “trial&error” methods, the outcomes of in
silico modeling are based on the knowledge of in vivo processes, and planning of the optimal
formulation strategy depending on drug biopharmaceutical properties and physiological
characteristics of the target population. The selected examples will demonstrate the basic
principles of in silico modeling in the development of pharmaceutical formulations.
AB  - Primena računarski podržanih (in silico) metoda modelovanja i simulacija postala je
globalni trend u različitim oblastima nauke, uključujući i farmaceutske nauke. Poslednjih
godina ove metode nalaze sve širu primenu u različitim fazama razvoja leka, od definisanja
strategije za razvoj formulacije, preko izbora odgovarajuće doze leka i optimalne formulacije
za kliničke studije, do predviđanja apsorpcije i dispozicije leka u različitim populacijama
pacijenta, identifikacije potencijalnih lek-lek interakcija, predviđanja ishoda studija biološke
ekvivalencije i argumentovanja biowaiver-a (1). Programi za in silico simulaciju/predviđanje
“ponašanja leka u organizmu” predstavljaju tzv. fiziološki-zasnovane modele, bazirane na
saznanjima o fiziološkim uslovima i procesima kojima lek podleže u organizmu, kao i
primeni odgovarajućih matematičkih relacija kojima je ove procese moguće opisati. Stoga
predstavljaju korisno sredstvo, ne samo za predviđanje očekivanih terapijskih ishoda koji
prate primenu leka, već i za testiranje hipoteza, odnosno, identifikaciju mehanizama koji su
odgovorni za fenomene kojima lek podleže in vivo. Drugim rečima, predstavljaju digitalni
prozor u “putovanje leka kroz organizam”. Fiziološki-zasnovani modeli se kontinuirano
unapređuju, te su relativno jednostavni modeli evolirali u tzv. model-zasnovane platforme za
razvoj lekova, što je na neki način pokrenulo revoluciju u oblasti istraživanja i razvoja lekova.
Za razliku od tradicionalnih metoda „pokušaja i greške“, ishodi in silico modelovanja su
zasnovani na poznavanju procesa koji se dešavaju in vivo i planiranju optimalne strategije za
razvoj formulacije, u zavisnosti od biofarmaceutskih svojstava lekovite supstance i
fizioloških karakteristika ciljane populacije pacijenata. U ovom izlaganju će, na odabranim
primerima, biti prikazani osnovni principi in silico modelovanja u razvoju formulacija
farmaceutskih preparata.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Physiologically based modeling in the development of novel drugs: Digital window to drug’s journey through the body
T1  - Primena fiziološki zasnovanog modelovanja u razvoju inovativnih lekova: digitalni prozor u putovanje leka kroz organizam
VL  - 72
IS  - 4 suplement
SP  - S81
EP  - S82
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4455
ER  - 

@conference{
author = "Cvijić, Sandra",
year = "2022",
abstract = "The application of computer-based (in silico) modeling&simulation tools has become a
global trend in different areas of science, including pharmaceutical sciences. These methods
have been increasingly used in different phases of formulation development, starting with
defining a sound formulation strategy, through the selection of drug dose and optimal
formulation for clinical studies, to the prediction of drug absorption/disposition in different
populations, identification of potential drug-drug interactions, prediction of bioequivalence
study outcomes and justification of biowaivers (1). In silico tools for the prediction of drug
bioperformance incorporate the so called physiologically-based models i.e., systems of data
on physiological conditions and processes a drug undergoes in the organism, with an
adequate mathematical background to describe these processes. As such, these models allow
prediction of the expected therapeutic outcomes following drug administration, and offer a
distinctive opportunity to test hypotheses and identify the underlying mechanisms
responsible for the phenomena a drug undergoes in vivo. In other words, they act as a digital
window to “drug’s journey through the body”. Physiologically-based models have been
upgraded continuously, and relatively simple models evolved into the model-based drug
development platforms, initiating a transformational change in drug formulation
research&development. Opposed to the traditional “trial&error” methods, the outcomes of in
silico modeling are based on the knowledge of in vivo processes, and planning of the optimal
formulation strategy depending on drug biopharmaceutical properties and physiological
characteristics of the target population. The selected examples will demonstrate the basic
principles of in silico modeling in the development of pharmaceutical formulations., Primena računarski podržanih (in silico) metoda modelovanja i simulacija postala je
globalni trend u različitim oblastima nauke, uključujući i farmaceutske nauke. Poslednjih
godina ove metode nalaze sve širu primenu u različitim fazama razvoja leka, od definisanja
strategije za razvoj formulacije, preko izbora odgovarajuće doze leka i optimalne formulacije
za kliničke studije, do predviđanja apsorpcije i dispozicije leka u različitim populacijama
pacijenta, identifikacije potencijalnih lek-lek interakcija, predviđanja ishoda studija biološke
ekvivalencije i argumentovanja biowaiver-a (1). Programi za in silico simulaciju/predviđanje
“ponašanja leka u organizmu” predstavljaju tzv. fiziološki-zasnovane modele, bazirane na
saznanjima o fiziološkim uslovima i procesima kojima lek podleže u organizmu, kao i
primeni odgovarajućih matematičkih relacija kojima je ove procese moguće opisati. Stoga
predstavljaju korisno sredstvo, ne samo za predviđanje očekivanih terapijskih ishoda koji
prate primenu leka, već i za testiranje hipoteza, odnosno, identifikaciju mehanizama koji su
odgovorni za fenomene kojima lek podleže in vivo. Drugim rečima, predstavljaju digitalni
prozor u “putovanje leka kroz organizam”. Fiziološki-zasnovani modeli se kontinuirano
unapređuju, te su relativno jednostavni modeli evolirali u tzv. model-zasnovane platforme za
razvoj lekova, što je na neki način pokrenulo revoluciju u oblasti istraživanja i razvoja lekova.
Za razliku od tradicionalnih metoda „pokušaja i greške“, ishodi in silico modelovanja su
zasnovani na poznavanju procesa koji se dešavaju in vivo i planiranju optimalne strategije za
razvoj formulacije, u zavisnosti od biofarmaceutskih svojstava lekovite supstance i
fizioloških karakteristika ciljane populacije pacijenata. U ovom izlaganju će, na odabranim
primerima, biti prikazani osnovni principi in silico modelovanja u razvoju formulacija
farmaceutskih preparata.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Physiologically based modeling in the development of novel drugs: Digital window to drug’s journey through the body, Primena fiziološki zasnovanog modelovanja u razvoju inovativnih lekova: digitalni prozor u putovanje leka kroz organizam",
volume = "72",
number = "4 suplement",
pages = "S81-S82",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4455"
}

Cvijić, S.. (2022). Physiologically based modeling in the development of novel drugs: Digital window to drug’s journey through the body. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S81-S82.
https://hdl.handle.net/21.15107/rcub_farfar_4455

Cvijić S. Physiologically based modeling in the development of novel drugs: Digital window to drug’s journey through the body. in Arhiv za farmaciju. 2022;72(4 suplement):S81-S82.
https://hdl.handle.net/21.15107/rcub_farfar_4455 .

Cvijić, Sandra, "Physiologically based modeling in the development of novel drugs: Digital window to drug’s journey through the body" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S81-S82,
https://hdl.handle.net/21.15107/rcub_farfar_4455 .

TY  - JOUR
AU  - Đuriš, Jelena
AU  - Pilović, Jovana
AU  - Džunić, Marina
AU  - Cvijić, Sandra
AU  - Ibrić, Svetlana
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4412
AB  - Text mining (TM) applications in the field of biomedicine are gaining great interest. TM
tools can facilitate formulation development by analyzing textual information from patent
databases, scientific articles, summary of products characteristics, etc. The aim of this study was
to utilize TM tools to perform qualitative analysis of paracetamol (PAR) and ibuprofen (IBU)
formulations, in terms of identifying and evaluating the presence of excipients specific to the
active pharmaceutical ingredient (API) and/or dosage form. A total of 152 products were
analyzed. Web-scraping was used to retrieve the data, and Python-based open-source software
Orange 3.31.1 was used for TM and statistical analysis (ANOVA) of the obtained results. The
majority of marketed products for both APIs were tablets. The predominant excipients in all tablet
formulations were povidone, starch, microcrystalline cellulose and hypromellose. Povidone,
stearic acid, potassium sorbate, maize starch and pregelatinized starch occurred more frequently
in PAR tablets. On the other hand, titanium dioxide, lactose, shellac, sucrose and ammonium
hydroxide were specific to IBU tablets. PAR oral suspensions more frequently contained
dispersible cellulose; liquid sorbitol; methyl and propyl parahydroxybenzoate, glycerol and
acesulfame potassium. Specific excipients in other PAR dosage forms, such as effervescent
tablets, hard capsules, oral powders, solutions and suspensions, as well as IBU gels and soft
capsules, were also evaluated.
AB  - Primena text mining (TM) alata u oblasti biomedicine postaje sve značajnija. TM alati mogu da olakšaju razvoj formulacija, tako što omogućavaju analizu tekstualnih informacija iz patentnih baza, naučnih članaka, sažetaka karakteristika lekova, itd. Cilj ovog rada bila je primena TM alata za kvalitativnu analizu formulacija paracetamola (PAR) i ibuprofena (IBU), u smislu identifikacije i procene prisustva ekscipijenasa koji su karakteristični za lekovitu supstancu i/ili farmaceutski oblik. Ukupno je analiziran sastav 152 preparata. Web-scraping je primenjen za prikupljanje podataka, a Orange 3.31.1, softver otvorenog koda zasnovan na programskom jeziku Python, primenjen je za TM i statističku analizu (ANOVA) dobijenih rezultata. Većina analiziranih formulacija za obe lekovite supstance bile su tablete, a najzastupljeniji ekscipijensi u njima su bili povidon, skrob, mikrokristalna celuloza i hipromeloza. Povidon, stearinska kiselina, kalijum sorbat, kukuruzni skrob i pregelirani skrob se češće pronalaze u formulacijama PAR tableta. Titanijum-dioksid, laktoza, šelak, saharoza i amonijum hidroksid su specifični za IBU tablete. PAR peroralne suspenzije su češće sadržale disperzibilnu celulozu; tečni sorbitol; metil-i propil parahidroksibenzoat, glicerol i acesulfam-kalijum. Takođe su identifikovani i specifični ekscipijensi za PAR efervescentne tablete, tvrde kapsule, peroralne praškove, rastvore i suspenzije, kao i za IBU gelove i meke kapsule.
PB  - Pharmaceutical Association of Serbia
T2  - Arhiv za farmaciju
T1  - Application of text-mining techniques for extraction and analysis of paracetamol and ibuprofen marketed products’ qualitative composition
T1  - Primena tehnika za sistematizovanu obradu tekstualnih informacija u cilju analize kvalitativnog sastava registrovanih preparata paracetamola i ibuprofena
VL  - 72
IS  - 6
SP  - 689
EP  - 700
DO  - 10.5937/arhfarm72-40397
ER  - 

@article{
author = "Đuriš, Jelena and Pilović, Jovana and Džunić, Marina and Cvijić, Sandra and Ibrić, Svetlana",
year = "2022",
abstract = "Text mining (TM) applications in the field of biomedicine are gaining great interest. TM
tools can facilitate formulation development by analyzing textual information from patent
databases, scientific articles, summary of products characteristics, etc. The aim of this study was
to utilize TM tools to perform qualitative analysis of paracetamol (PAR) and ibuprofen (IBU)
formulations, in terms of identifying and evaluating the presence of excipients specific to the
active pharmaceutical ingredient (API) and/or dosage form. A total of 152 products were
analyzed. Web-scraping was used to retrieve the data, and Python-based open-source software
Orange 3.31.1 was used for TM and statistical analysis (ANOVA) of the obtained results. The
majority of marketed products for both APIs were tablets. The predominant excipients in all tablet
formulations were povidone, starch, microcrystalline cellulose and hypromellose. Povidone,
stearic acid, potassium sorbate, maize starch and pregelatinized starch occurred more frequently
in PAR tablets. On the other hand, titanium dioxide, lactose, shellac, sucrose and ammonium
hydroxide were specific to IBU tablets. PAR oral suspensions more frequently contained
dispersible cellulose; liquid sorbitol; methyl and propyl parahydroxybenzoate, glycerol and
acesulfame potassium. Specific excipients in other PAR dosage forms, such as effervescent
tablets, hard capsules, oral powders, solutions and suspensions, as well as IBU gels and soft
capsules, were also evaluated., Primena text mining (TM) alata u oblasti biomedicine postaje sve značajnija. TM alati mogu da olakšaju razvoj formulacija, tako što omogućavaju analizu tekstualnih informacija iz patentnih baza, naučnih članaka, sažetaka karakteristika lekova, itd. Cilj ovog rada bila je primena TM alata za kvalitativnu analizu formulacija paracetamola (PAR) i ibuprofena (IBU), u smislu identifikacije i procene prisustva ekscipijenasa koji su karakteristični za lekovitu supstancu i/ili farmaceutski oblik. Ukupno je analiziran sastav 152 preparata. Web-scraping je primenjen za prikupljanje podataka, a Orange 3.31.1, softver otvorenog koda zasnovan na programskom jeziku Python, primenjen je za TM i statističku analizu (ANOVA) dobijenih rezultata. Većina analiziranih formulacija za obe lekovite supstance bile su tablete, a najzastupljeniji ekscipijensi u njima su bili povidon, skrob, mikrokristalna celuloza i hipromeloza. Povidon, stearinska kiselina, kalijum sorbat, kukuruzni skrob i pregelirani skrob se češće pronalaze u formulacijama PAR tableta. Titanijum-dioksid, laktoza, šelak, saharoza i amonijum hidroksid su specifični za IBU tablete. PAR peroralne suspenzije su češće sadržale disperzibilnu celulozu; tečni sorbitol; metil-i propil parahidroksibenzoat, glicerol i acesulfam-kalijum. Takođe su identifikovani i specifični ekscipijensi za PAR efervescentne tablete, tvrde kapsule, peroralne praškove, rastvore i suspenzije, kao i za IBU gelove i meke kapsule.",
publisher = "Pharmaceutical Association of Serbia",
journal = "Arhiv za farmaciju",
title = "Application of text-mining techniques for extraction and analysis of paracetamol and ibuprofen marketed products’ qualitative composition, Primena tehnika za sistematizovanu obradu tekstualnih informacija u cilju analize kvalitativnog sastava registrovanih preparata paracetamola i ibuprofena",
volume = "72",
number = "6",
pages = "689-700",
doi = "10.5937/arhfarm72-40397"
}

Đuriš, J., Pilović, J., Džunić, M., Cvijić, S.,& Ibrić, S.. (2022). Application of text-mining techniques for extraction and analysis of paracetamol and ibuprofen marketed products’ qualitative composition. in Arhiv za farmaciju
Pharmaceutical Association of Serbia., 72(6), 689-700.
https://doi.org/10.5937/arhfarm72-40397

Đuriš J, Pilović J, Džunić M, Cvijić S, Ibrić S. Application of text-mining techniques for extraction and analysis of paracetamol and ibuprofen marketed products’ qualitative composition. in Arhiv za farmaciju. 2022;72(6):689-700.
doi:10.5937/arhfarm72-40397 .

Đuriš, Jelena, Pilović, Jovana, Džunić, Marina, Cvijić, Sandra, Ibrić, Svetlana, "Application of text-mining techniques for extraction and analysis of paracetamol and ibuprofen marketed products’ qualitative composition" in Arhiv za farmaciju, 72, no. 6 (2022):689-700,
https://doi.org/10.5937/arhfarm72-40397 . .

TY  - JOUR
AU  - Cvijić, Sandra
AU  - Mirković, Dušica
AU  - Krajišnik, Danina
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4260
AB  - The treatment of respiratory infections in children requires special attention, since the
paediatric population has rather specific characteristics and consists of heterogenous subgroups.
In this context, the choice of a suitable drug dosage form is of particular importance, depending
on the active substance properties, along with the age and general condition of a paediatric patient.
Тhe most commonly used pharmaceutical products for respiratory infections in children include
oral, parenteral and inhalation dosage forms, although a large number of drugs are not available
in a suitable dosage form and/or strength for paediatric age, leading to the frequent use of
unauthorized drugs (i.e., unlicensed use). Other important issues that should be considered when
choosing the appropriate paediatric dosage form and/or compounding procedure are related to the
careful considerations of the pharmaceutical product composition (safety of excipients) and the
choice of administration/dosing device in relation to a child’s age.
This paper provides an overview of paediatric dosage forms used in the treatment of
respiratory infections in children, their benefits and limitations. The review includes examples of
various pharmaceutical products, along with the considerations regarding administration/dosing
devices. Specific characteristics of paediatric populations affecting the decision on the choice of
age-appropriate paediatric formulation are also addressed.
AB  - Terapija respiratornih infekcija kod dece zahteva posebnu pažnju, jer ovu populaciju čini specifična i izuzetno heterogena grupa pacijenata. Veoma je važno odabrati odgovarajući farmaceutski oblik leka, u skladu sa karakteristikama aktivne supstance, kao i stanjem i uzrastom deteta. U praksi se, u terapiji respiratornih infekcija kod dece, najviše koriste preparati za oralnu primenu, za parenteralnu primenu i za inhalaciju. Međutim, veliki broj lekova nije dostupan u odgovarajućem farmaceutskom obliku i/ili jačini za pedijatrijski uzrast, usled čega je česta neodobrena upotreba lekova. Prilikom izbora/izrade preparata za decu potrebno je pažljivo razmotriti i sastav preparata (bezbednost pomoćnih supstanci), kao i izbor aplikatora, u skladu sa uzrastom deteta. U ovom radu je dat prikaz farmaceutskih oblika lekova koji se koriste u terapiji respiratornih infekcija kod dece, njihovih prednosti i izvesnih nedostataka. Navedeni su različiti primeri farmaceutskih preparata, uz poseban osvrt na izbor aplikatora za primenu/doziranje lekova. Takođe, diskutovane su specifičnosti pedijatrijske populacije koje utiču na izbor odgovarajuće formulacije leka prilagođene uzrastu deteta.
PB  - Beograd : Savez farmaceutskih udruženja Srbije
T2  - Arhiv za farmaciju
T1  - How to choose an appropriate drug dosage form for the treatment of respiratory infections in children: Facts and tips
T1  - Stavovi i saveti vezani za izbor farmaceutskih oblika lekova za lečenje respiratornih infekcija kod dece
VL  - 72
IS  - 3
SP  - 353
EP  - 372
DO  - 10.5937/arhfarm72-37643
ER  - 

@article{
author = "Cvijić, Sandra and Mirković, Dušica and Krajišnik, Danina",
year = "2022",
abstract = "The treatment of respiratory infections in children requires special attention, since the
paediatric population has rather specific characteristics and consists of heterogenous subgroups.
In this context, the choice of a suitable drug dosage form is of particular importance, depending
on the active substance properties, along with the age and general condition of a paediatric patient.
Тhe most commonly used pharmaceutical products for respiratory infections in children include
oral, parenteral and inhalation dosage forms, although a large number of drugs are not available
in a suitable dosage form and/or strength for paediatric age, leading to the frequent use of
unauthorized drugs (i.e., unlicensed use). Other important issues that should be considered when
choosing the appropriate paediatric dosage form and/or compounding procedure are related to the
careful considerations of the pharmaceutical product composition (safety of excipients) and the
choice of administration/dosing device in relation to a child’s age.
This paper provides an overview of paediatric dosage forms used in the treatment of
respiratory infections in children, their benefits and limitations. The review includes examples of
various pharmaceutical products, along with the considerations regarding administration/dosing
devices. Specific characteristics of paediatric populations affecting the decision on the choice of
age-appropriate paediatric formulation are also addressed., Terapija respiratornih infekcija kod dece zahteva posebnu pažnju, jer ovu populaciju čini specifična i izuzetno heterogena grupa pacijenata. Veoma je važno odabrati odgovarajući farmaceutski oblik leka, u skladu sa karakteristikama aktivne supstance, kao i stanjem i uzrastom deteta. U praksi se, u terapiji respiratornih infekcija kod dece, najviše koriste preparati za oralnu primenu, za parenteralnu primenu i za inhalaciju. Međutim, veliki broj lekova nije dostupan u odgovarajućem farmaceutskom obliku i/ili jačini za pedijatrijski uzrast, usled čega je česta neodobrena upotreba lekova. Prilikom izbora/izrade preparata za decu potrebno je pažljivo razmotriti i sastav preparata (bezbednost pomoćnih supstanci), kao i izbor aplikatora, u skladu sa uzrastom deteta. U ovom radu je dat prikaz farmaceutskih oblika lekova koji se koriste u terapiji respiratornih infekcija kod dece, njihovih prednosti i izvesnih nedostataka. Navedeni su različiti primeri farmaceutskih preparata, uz poseban osvrt na izbor aplikatora za primenu/doziranje lekova. Takođe, diskutovane su specifičnosti pedijatrijske populacije koje utiču na izbor odgovarajuće formulacije leka prilagođene uzrastu deteta.",
publisher = "Beograd : Savez farmaceutskih udruženja Srbije",
journal = "Arhiv za farmaciju",
title = "How to choose an appropriate drug dosage form for the treatment of respiratory infections in children: Facts and tips, Stavovi i saveti vezani za izbor farmaceutskih oblika lekova za lečenje respiratornih infekcija kod dece",
volume = "72",
number = "3",
pages = "353-372",
doi = "10.5937/arhfarm72-37643"
}

Cvijić, S., Mirković, D.,& Krajišnik, D.. (2022). How to choose an appropriate drug dosage form for the treatment of respiratory infections in children: Facts and tips. in Arhiv za farmaciju
Beograd : Savez farmaceutskih udruženja Srbije., 72(3), 353-372.
https://doi.org/10.5937/arhfarm72-37643

Cvijić S, Mirković D, Krajišnik D. How to choose an appropriate drug dosage form for the treatment of respiratory infections in children: Facts and tips. in Arhiv za farmaciju. 2022;72(3):353-372.
doi:10.5937/arhfarm72-37643 .

Cvijić, Sandra, Mirković, Dušica, Krajišnik, Danina, "How to choose an appropriate drug dosage form for the treatment of respiratory infections in children: Facts and tips" in Arhiv za farmaciju, 72, no. 3 (2022):353-372,
https://doi.org/10.5937/arhfarm72-37643 . .

TY  - CONF
AU  - Glišić, Teodora
AU  - Petrović, Jovana
AU  - Cvijić, Sandra
AU  - Parojčić, Jelena
AU  - Aleksić, Ivana
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5525
AB  - Development of novel porous excipients with high specific surface area enabled formulation of
liquisolid systems with considerably increased content of liquid drug (or drug solution/suspension)
in comparison to those prepared with commonly used carriers, such as microcrystalline cellulose,
while ensuring good flowability.  ...
PB  - Medical University of Gdansk
PB  - Polskie Towarzystwo Farmaceutyczne
C3  - Proceedings CESPT 2021: 13th Central European Symposium on Pharmaceutical Technology: Contemporary pharmaceutical technology - addressing challenges of innovative and generic medicinal products, 16th-18th September 2021, Gdansk, Poland
T1  - Dynamic compaction analysis of liquisolid systems with magnesium aluminometasilicate as carrier
SP  - 114
EP  - 115
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5525
ER  - 

@conference{
author = "Glišić, Teodora and Petrović, Jovana and Cvijić, Sandra and Parojčić, Jelena and Aleksić, Ivana",
year = "2021",
abstract = "Development of novel porous excipients with high specific surface area enabled formulation of
liquisolid systems with considerably increased content of liquid drug (or drug solution/suspension)
in comparison to those prepared with commonly used carriers, such as microcrystalline cellulose,
while ensuring good flowability.  ...",
publisher = "Medical University of Gdansk, Polskie Towarzystwo Farmaceutyczne",
journal = "Proceedings CESPT 2021: 13th Central European Symposium on Pharmaceutical Technology: Contemporary pharmaceutical technology - addressing challenges of innovative and generic medicinal products, 16th-18th September 2021, Gdansk, Poland",
title = "Dynamic compaction analysis of liquisolid systems with magnesium aluminometasilicate as carrier",
pages = "114-115",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5525"
}

Glišić, T., Petrović, J., Cvijić, S., Parojčić, J.,& Aleksić, I.. (2021). Dynamic compaction analysis of liquisolid systems with magnesium aluminometasilicate as carrier. in Proceedings CESPT 2021: 13th Central European Symposium on Pharmaceutical Technology: Contemporary pharmaceutical technology - addressing challenges of innovative and generic medicinal products, 16th-18th September 2021, Gdansk, Poland
Medical University of Gdansk., 114-115.
https://hdl.handle.net/21.15107/rcub_farfar_5525

Glišić T, Petrović J, Cvijić S, Parojčić J, Aleksić I. Dynamic compaction analysis of liquisolid systems with magnesium aluminometasilicate as carrier. in Proceedings CESPT 2021: 13th Central European Symposium on Pharmaceutical Technology: Contemporary pharmaceutical technology - addressing challenges of innovative and generic medicinal products, 16th-18th September 2021, Gdansk, Poland. 2021;:114-115.
https://hdl.handle.net/21.15107/rcub_farfar_5525 .

Glišić, Teodora, Petrović, Jovana, Cvijić, Sandra, Parojčić, Jelena, Aleksić, Ivana, "Dynamic compaction analysis of liquisolid systems with magnesium aluminometasilicate as carrier" in Proceedings CESPT 2021: 13th Central European Symposium on Pharmaceutical Technology: Contemporary pharmaceutical technology - addressing challenges of innovative and generic medicinal products, 16th-18th September 2021, Gdansk, Poland (2021):114-115,
https://hdl.handle.net/21.15107/rcub_farfar_5525 .

TY  - CONF
AU  - Aleksić, Ivana
AU  - Vasiljević, Ivana
AU  - Glišić, Teodora
AU  - Cvijić, Sandra
AU  - Parojčić, Jelena
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5316
AB  - Liquisolid technology has gained an increased attention as a
promising approach for the improvement of bioavailability
of poorly water soluble drugs. Suitable excipients with high
surface area and porous structure are used to convert liquid
lipophilic drugs or drug solutions/suspensions to powder
suitable for filling into capsules or compression into tablets.
Spireas (1) proposed this approach and pointed out the
importance of selecting the appropriate excipients (carrier
and coating material) in optimum amounts in order to
achieve both good flowability and acceptable compaction
properties, as prerequisites for industrial application.
Compaction properties of liquisolid systems have been
recognized as particularly challenging. However, the
published results regarding compression behavior of
liquisolid systems are still very limited (2, 3).
In the present study mesoporous, amorphous silica
excipients (Syloid® XDP 3050 and XDP 3150), optimized
to be used as carriers in liquisolid systems, were used for
preparation of liquisolid compacts. The aim of this study
was to evaluate the influence of carrier to coating ratio and
liquid content on flowability and compaction behavior of
liquisolid systems prepared with these novel excipients.
PB  - International Association for Pharmaceutical Technology, Mainz, Germany
C3  - 12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, 11th-14th May 2021, Vienna, Austria, Virtual meeting
T1  - Liquisolid systems with mesoporous silica based carriers: An investigation of flow and compaction properties
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5316
ER  - 

@conference{
author = "Aleksić, Ivana and Vasiljević, Ivana and Glišić, Teodora and Cvijić, Sandra and Parojčić, Jelena",
year = "2021",
abstract = "Liquisolid technology has gained an increased attention as a
promising approach for the improvement of bioavailability
of poorly water soluble drugs. Suitable excipients with high
surface area and porous structure are used to convert liquid
lipophilic drugs or drug solutions/suspensions to powder
suitable for filling into capsules or compression into tablets.
Spireas (1) proposed this approach and pointed out the
importance of selecting the appropriate excipients (carrier
and coating material) in optimum amounts in order to
achieve both good flowability and acceptable compaction
properties, as prerequisites for industrial application.
Compaction properties of liquisolid systems have been
recognized as particularly challenging. However, the
published results regarding compression behavior of
liquisolid systems are still very limited (2, 3).
In the present study mesoporous, amorphous silica
excipients (Syloid® XDP 3050 and XDP 3150), optimized
to be used as carriers in liquisolid systems, were used for
preparation of liquisolid compacts. The aim of this study
was to evaluate the influence of carrier to coating ratio and
liquid content on flowability and compaction behavior of
liquisolid systems prepared with these novel excipients.",
publisher = "International Association for Pharmaceutical Technology, Mainz, Germany",
journal = "12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, 11th-14th May 2021, Vienna, Austria, Virtual meeting",
title = "Liquisolid systems with mesoporous silica based carriers: An investigation of flow and compaction properties",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5316"
}

Aleksić, I., Vasiljević, I., Glišić, T., Cvijić, S.,& Parojčić, J.. (2021). Liquisolid systems with mesoporous silica based carriers: An investigation of flow and compaction properties. in 12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, 11th-14th May 2021, Vienna, Austria, Virtual meeting
International Association for Pharmaceutical Technology, Mainz, Germany..
https://hdl.handle.net/21.15107/rcub_farfar_5316

Aleksić I, Vasiljević I, Glišić T, Cvijić S, Parojčić J. Liquisolid systems with mesoporous silica based carriers: An investigation of flow and compaction properties. in 12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, 11th-14th May 2021, Vienna, Austria, Virtual meeting. 2021;.
https://hdl.handle.net/21.15107/rcub_farfar_5316 .

Aleksić, Ivana, Vasiljević, Ivana, Glišić, Teodora, Cvijić, Sandra, Parojčić, Jelena, "Liquisolid systems with mesoporous silica based carriers: An investigation of flow and compaction properties" in 12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, 11th-14th May 2021, Vienna, Austria, Virtual meeting (2021),
https://hdl.handle.net/21.15107/rcub_farfar_5316 .

TY  - CONF
AU  - Đoković, Nemanja
AU  - Ružić, Dušan
AU  - Đikić, Teodora
AU  - Cvijić, Sandra
AU  - Ignjatović, Jelisaveta
AU  - Ibrić, Svetlana
AU  - Baralić, Katarina
AU  - Buha-Đorđević, Aleksandra
AU  - Ćurčić, Marijana
AU  - Đukić-Ćosić, Danijela
AU  - Nikolić, Katarina
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4896
PB  - Hellenic Society of Medicinal Chemistry
C3  - 18th Hellenic Symposium on Medicinal Chemistry, 25 - 27 February 2021, Online Symposium
T1  - Seeking SARS-CoV-2 Mpro inhibitors through an integrative in silico approach
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4896
ER  - 

@conference{
author = "Đoković, Nemanja and Ružić, Dušan and Đikić, Teodora and Cvijić, Sandra and Ignjatović, Jelisaveta and Ibrić, Svetlana and Baralić, Katarina and Buha-Đorđević, Aleksandra and Ćurčić, Marijana and Đukić-Ćosić, Danijela and Nikolić, Katarina",
year = "2021",
publisher = "Hellenic Society of Medicinal Chemistry",
journal = "18th Hellenic Symposium on Medicinal Chemistry, 25 - 27 February 2021, Online Symposium",
title = "Seeking SARS-CoV-2 Mpro inhibitors through an integrative in silico approach",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4896"
}

Đoković, N., Ružić, D., Đikić, T., Cvijić, S., Ignjatović, J., Ibrić, S., Baralić, K., Buha-Đorđević, A., Ćurčić, M., Đukić-Ćosić, D.,& Nikolić, K.. (2021). Seeking SARS-CoV-2 Mpro inhibitors through an integrative in silico approach. in 18th Hellenic Symposium on Medicinal Chemistry, 25 - 27 February 2021, Online Symposium
Hellenic Society of Medicinal Chemistry..
https://hdl.handle.net/21.15107/rcub_farfar_4896

Đoković N, Ružić D, Đikić T, Cvijić S, Ignjatović J, Ibrić S, Baralić K, Buha-Đorđević A, Ćurčić M, Đukić-Ćosić D, Nikolić K. Seeking SARS-CoV-2 Mpro inhibitors through an integrative in silico approach. in 18th Hellenic Symposium on Medicinal Chemistry, 25 - 27 February 2021, Online Symposium. 2021;.
https://hdl.handle.net/21.15107/rcub_farfar_4896 .

Đoković, Nemanja, Ružić, Dušan, Đikić, Teodora, Cvijić, Sandra, Ignjatović, Jelisaveta, Ibrić, Svetlana, Baralić, Katarina, Buha-Đorđević, Aleksandra, Ćurčić, Marijana, Đukić-Ćosić, Danijela, Nikolić, Katarina, "Seeking SARS-CoV-2 Mpro inhibitors through an integrative in silico approach" in 18th Hellenic Symposium on Medicinal Chemistry, 25 - 27 February 2021, Online Symposium (2021),
https://hdl.handle.net/21.15107/rcub_farfar_4896 .

TY  - JOUR
AU  - Đuranović, Marija
AU  - Madžarević, Marijana
AU  - Ivković, Branka
AU  - Ibrić, Svetlana
AU  - Cvijić, Sandra
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4088
AB  - Paracetamol-loaded tablets were printed by fused deposition modelling technique, using polyvinyl alcohol as a backbone polymer and Affinisol™ HPMC as a plasticizer in all formulations. Four different strategies were applied in order to accelerate the drug release from the tablets. First, different release enhancers were added: sodium starch glycolate, croscarmellose sodium, Kollidon CL and mannitol. Kollidon CL and mannitol showed the greatest influence on the drug dissolution rate. The second strategy included lowering the infill density, which did not make any significant changes in dissolution profiles, according to the calculated similarity factor. Then the best two release enhancers from the first strategy were combined (Kollidon CL and mannitol) and this proved to be the most effective in the drug release acceleration. The fourth strategy, increasing the percentage of the release enhancers in formulation, revealed the importance of their concentration limits. In summary, the drug release accelerated from 58% released after 5 h to reaching the plateau within 2 h. In silico physiologically-based biopharmaceutics modelling showed that formulations with mannitol and Kollidon CL, especially the formulation containing a combination of these release enhancers, can provide relatively fast drug release and extent of drug absorption that complies with an immediate release tablet.
PB  - Elsevier B.V.
T2  - International Journal of Pharmaceutics
T1  - The evaluation of the effect of different superdisintegrants on the drug release from FDM 3D printed tablets through different applied strategies: In vitro-in silico assessment
VL  - 610
DO  - 10.1016/j.ijpharm.2021.121194
ER  - 

@article{
author = "Đuranović, Marija and Madžarević, Marijana and Ivković, Branka and Ibrić, Svetlana and Cvijić, Sandra",
year = "2021",
abstract = "Paracetamol-loaded tablets were printed by fused deposition modelling technique, using polyvinyl alcohol as a backbone polymer and Affinisol™ HPMC as a plasticizer in all formulations. Four different strategies were applied in order to accelerate the drug release from the tablets. First, different release enhancers were added: sodium starch glycolate, croscarmellose sodium, Kollidon CL and mannitol. Kollidon CL and mannitol showed the greatest influence on the drug dissolution rate. The second strategy included lowering the infill density, which did not make any significant changes in dissolution profiles, according to the calculated similarity factor. Then the best two release enhancers from the first strategy were combined (Kollidon CL and mannitol) and this proved to be the most effective in the drug release acceleration. The fourth strategy, increasing the percentage of the release enhancers in formulation, revealed the importance of their concentration limits. In summary, the drug release accelerated from 58% released after 5 h to reaching the plateau within 2 h. In silico physiologically-based biopharmaceutics modelling showed that formulations with mannitol and Kollidon CL, especially the formulation containing a combination of these release enhancers, can provide relatively fast drug release and extent of drug absorption that complies with an immediate release tablet.",
publisher = "Elsevier B.V.",
journal = "International Journal of Pharmaceutics",
title = "The evaluation of the effect of different superdisintegrants on the drug release from FDM 3D printed tablets through different applied strategies: In vitro-in silico assessment",
volume = "610",
doi = "10.1016/j.ijpharm.2021.121194"
}

Đuranović, M., Madžarević, M., Ivković, B., Ibrić, S.,& Cvijić, S.. (2021). The evaluation of the effect of different superdisintegrants on the drug release from FDM 3D printed tablets through different applied strategies: In vitro-in silico assessment. in International Journal of Pharmaceutics
Elsevier B.V.., 610.
https://doi.org/10.1016/j.ijpharm.2021.121194

Đuranović M, Madžarević M, Ivković B, Ibrić S, Cvijić S. The evaluation of the effect of different superdisintegrants on the drug release from FDM 3D printed tablets through different applied strategies: In vitro-in silico assessment. in International Journal of Pharmaceutics. 2021;610.
doi:10.1016/j.ijpharm.2021.121194 .

Đuranović, Marija, Madžarević, Marijana, Ivković, Branka, Ibrić, Svetlana, Cvijić, Sandra, "The evaluation of the effect of different superdisintegrants on the drug release from FDM 3D printed tablets through different applied strategies: In vitro-in silico assessment" in International Journal of Pharmaceutics, 610 (2021),
https://doi.org/10.1016/j.ijpharm.2021.121194 . .